Identification of differentially expressed proteins in obese rats fed different high fat diets using proteomics and bioinformatics approaches by Gabuza, Kwazikwakhe
Identification of differentially expressed proteins in obese rats fed different
high fat diets using proteomics and bioinformatics approaches
Kwazikwakhe Gabuza
A thesis submitted in fulfilment of the requirements for the degree of
Philosophiae Doctor in the Faculty of Science
Department of Biotechnology
University of the
Western Cape
May 2013
Supervisor:               Prof B. K. Ndimba
Co-supervisor: Dr A. M. Madiehe
 
 
 
 
ii
Abstract
Identification of differentially expressed proteins in obese rats fed different high
fat diets using proteomics and bioinformatics approaches
K. Gabuza
PhD Thesis, Department of Biotechnology, Faculty of Science, University of the
Western Cape, South Africa
Background
Obesity is a medical condition in which an energy imbalance leads to excessive
accumulation of body fat. Obesity leads to a reduction in life expectancy through its
association with chronic diseases of lifestyle. The prevalence of obesity is rapidly
increasing throughout the world. It is now accepted that most cases of obesity result
from an interaction between genetic and environmental factors. This rapid increase in
obesity generally leads to an increase in morbidity and mortality from chronic diseases
such as cardiovascular disease, type 2 diabetes, osteoarthritis and cancer of which
obesity is a risk factor. There is a lack of information in molecular research to explain
how obesity predisposes individuals to these diseases. Proteomics is a molecular tool
and a set of techniques used to identify changes at protein level from a diseased state.
This study aims to identify differentially expressed proteins in serum of obese rats fed
different isocaloric diets using proteomics.
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Methods
Twenty eight rats were used in this study. Twenty one male Wistar rats were fed three
isocaloric high fat diets, which are lard diet (L) (n=7), lard fat free diet (LF) (n=7) and
butterfat diet (BF) (n=7) to induce obesity. A control group was fed maintenance diet
(C) (n=7). The dietary composition for the diets was as follows: C (1.3% fat, 67%
CHO, 25% protein); L (35% fat, 50% CHO, 10% proteins); LF (19% fat, 57% CHO,
19% protein) and BF (15% fat, 59% CHO, 21% protein). The rats were body weight
matched and assigned to four groups. Food intake and body weights were measured
weekly. Blood glucose was measured using glucometer and blood collected at 0, 4
days, 4 weeks and 8 weeks of assigning rats to different groups. The serum was
prepared. The serum was subjected to 2D gel electrophoresis and PD Quest analysis.
Spots of interest were identified using MALDI TOF. Western blot was used to verify
the PD Quest results. A bioinformatics review of identified proteins was performed.
Results
Feeding high fat diets to rats resulted in a significant weight gain for L and LF groups
when compared to the C group (p < 0.001). The BF group weighed significantly more
compared to C group (p < 0.05). Nine spots from LF, seven spots from BF and eleven
spots from L were differentially expressed compared to those from C as determined by
PD Quest analysis. Of the differentially expressed spots, the up-regulated spots were
six, four and four for L, LF and BF, respectively. Down-regulated spots were five, four
and three for L, LF and BF respectively. Three upregulated spots were identified using
MALDI TOF MS to be Apolipoprotein AIV, C-reactive protein and Hemopexin-like.
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The down regulated spot was identified to be Alpha 1 macroglobulin-like protein.
Using a reference map, the other two proteins were identified to be Fetuin A and
Fetuin B. Western blotting verification of the findings confirmed the increased levels
of C-reactive protein for the L, LF and BF groups compared to the C group (p < 0.01).
Increased levels of Fetuin A and Fetuin B were also confirmed for L, LF, and BF
compared to C (p < 0.05). Western blotting also confirmed the results on
Apolipoprotein AIV with groups on high fat diets having significantly high levels
compared to the C group (p < 0.05). A bioinformatics analysis using Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway showed the C-reactive protein
to be involved in the nitrogen metabolism pathway. Apolipoprotein AIV seems to be
associated with the activation of the peroxisome proliferation activated receptor
(PPAR) signalling pathway.
Conclusion
This study managed to show the proteome variation that is brought about by obesity
development. Further studies are required to study the role of these proteins in
obesity pathogenesis and their usefulness as potential diagnostic/prognostic targets.
What this study managed to reveal is the responsive proteins during obesity
development and these proteins may be potential markers of obesity when studied in
depth.
Keywords: High fat diet, Diet induced obesity, 2D Gel, MALDI TOF MS,
Proteomics, Candidate biomarkers, Wistar rats, Serum, Western blot, differentially
expressed proteins
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1Chapter 1: Literature Review
1.1 Obesity: Prevalence, Diagnosis, Causes and Treatment
Obesity is a complex chronic disease that results from the interaction of multiple
genetic, cultural, socioeconomic, behavioural, physiologic, metabolic, cellular and
molecular influences. It took time for the full spectrum of diseases linked to obesity
to become apparent and for centuries obesity has been known to cause serious chronic
diseases. Obesity is associated with a high incidence of co morbidities, including
cardiovascular disease, type 2 (adult onset) diabetes, osteoarthritis and increased risk
for many forms of cancer (Strader et al., 1998). Coronary heart disease or heart
failure, osteoarthritis (knee), hyperuricaemia, gout complications and complications
of pregnancy e.g. eclampsia are amongst moderately increased risk health
consequences. Increased risk consequences associated with obesity are cancer,
impaired fertility/polycystic ovary syndrome, low back pain, increased risk during
anaesthesia and fatal defects arising from maternal obesity.
Obesity occurs as a result an energy imbalance which happens when energy intake is
greater than energy expenditure. The prevalence of obesity is rapidly increasing
throughout the world; this is mostly attributed to environmental factors with high
caloric diets on top of the list of these factors (Naderali and Williams, 2003). This is
also demonstrated in this study. Numerous factors influence body weight gain and
obesity and these therefore can be used to determine people at risk of developing
obesity and obesity-induced disorders.
 
 
 
 
2There are critical periods during development of obesity, the times during people’s
lives when exposure to certain factors may increase their risk for the onset of obesity.
The prenatal period, the adiposity rebound and adolescence are proposed to be critical
points in childhood. Pregnancy and the immediate postpartum period have been
proposed are critical periods for women in adulthood. There are other factors that can
influence body weight, factors that an individual has no control over. These include
developmental determinants, genetic makeup, gender and age (Dietz, 2001).
Alcohol, smoking and drug therapy also has a huge impact in obesity development.
Positive impact by  moderate alcohol consumption has been seen through the
reduction  of coronary artery disease (CAD). Half of the coronary artery disease
afforded by moderate alcohol consumption occurs through an increase in HDL
cholesterol. On the other hand excessive alcohol consumption can exacerbate
hypertension and  lead to stroke, liver disease, alcoholic cardiomyopathy, cardiac
dysrythmias and it also aggravates hypertriglyceridemia, which can be a problem in
persons with baseline levels >500mg/dL (Langer et al., 1992). Alcohol intake may
have an impact on body weight (Dietz, 2001). Excessive consumption could result in
excess energy being converted to fat (Dietz, 2001). Compared to non alcoholic
beverages drinking alcohol has been shown to be associated with a greater energy
intake which can be due to increased appetite. Despite alcohol’s beneficial effects on
CAD alcohol, should not be routinely prescribed since the benefits may not outweigh
the risks (Dietz, 2001).
 
 
 
 
3Smoking and obesity are not completely understood regarding their relationship. An
acute increase of energy expenditure (EE) and reduction of appetite by nicotine is
likely to be an explanation why smokers tend to have lower body weight than non-
smokers. Furthermore are observations in previous studies that show frequent body
weight gain that follows smoking cessation (Chiolero et al., 2008). Cigarette smoking
increases metabolic rate and may limit food intake. A study by Stamford et. al.,
(1986) reported that smoking cessation leads to significant weight gain of which 96%
of the weight is fat, increased caloric consumption which could account for 69% of
the weight gained over 48 days and a rise in HDL-C levels (Stamford et al., 1986). In
the same study it was found that the participants that return to smoking return to
baseline weight in 1 year. This study is followed by various studies that focus on
nicotine. A recent study revealed that nicotine temporarily reduces insulin sensitivity
by stimulating the secretion of tumor necrosis factor alpha (TNFα) and free fatty
acids (FFAs), whereas the long term stimulation of nicotinic acetylcholine receptors
(nAChRs) by nicotine, in addition to autonomic nervous stimulation, contributes to
better insulin sensitivity in vivo through the modulatory secretion of the
adipocytokines (Liu et al., 2004)
There are various drugs or pharmacological agents that produce weight gain.
Glucocorticoids, hypoglycemic agents, certain antihypertensive agents, anti-allergens
and numerous drugs that affect the central nervous system have been said to
impact on weight gain. Glucocorticoids might function peripherally to produce the
observed genotypic differences in the onset of fat accumulation and elevation of
plasma leptin, not only by favouring leptin production but also by inducing
 
 
 
 
4repartitioning of lipid storage in specific fat pads (subcutaneous fat) and the liver,
where gluconeogenesis is stimulated by corticosterone (Smart et al., 2006).
Hypoglycaemic agents are known to have side effects and the drugs that are known
to lead to weight gain are sulfonylureas and this is counteracted by the use of the
drugs in this class in combination with metformin (Zinman et al., 2010).
Racette et al., (2003) reported the prevalence of obesity based on age which shows
an increase w i t h  a n  i n c r e a s e  i n  a g e (Racette et al., 2003). Projections by
Odgen et. al. based on the body mass index showed 10.4 % of children 2 to 5 years
of age, 15.3% of children 6 to 11 years of age and 15.5% of children 12 to 19 years of
age to be overweight (Ogden et al., 2002). That explained the increase of diabetes of
the young back in the years and current. This shows an increase in obesity with an
increase in age. This study above focused on the situation in America, in contrast to
the study reported the same year by (Puoane et al., 2002) showed the situation to
decrease with age in South Africa. There were high obesity cases that were
going down with increase in age. This might be because of the change to the
situation that is now predominant amongst South Africans whereby children spend
more time indoors living passive life of television and computer games.
There  is data on different ethnic groups that has been collected over the years
focusing on obesity. National Health and Nutrition Examination Survey (NHANES)
indicated the ethnic differences in prevalence of overweight and obesity. The 1999-
 
 
 
 
52000 NHANES data reported men 20 years of age and older with BMI≥25 prevalence
to 67.4 percent for non-Hispanic whites, 60.7 percent for non-Hispanic blacks and
74.7 percent for Mexican Americans. In women 20 years of age and older the
prevalence of overweight was 57.3 percent in non-Hispanic whites, 77.3 percent for
non-Hispanic blacks and 71.9 percent in Mexican Americans. Puoane et al (2002)
reported on the race related prevalence of obesity in South Africa. Four major ethnic
groups are recognized in South Africa these include Africans, Coloureds, Indians and
Whites. According to the study by Puoane and colleagues they reported the
prevalence of obesity (BMI>30 kg/m2) in South African black women at 31-34% and
in white women at 18-24% (Puoane et al., 2002). In the Indian and coloured groups,
the prevalence in women is 20-22% and 26-28% respectively. The prevalence in
black, Indian and coloured men are 8%, 3-9% and 6-9% respectively, with the highest
in men occurring in whites (15-20%).
The prevalence of obesity is increasing in most African countries, particularly in
individuals living in urban areas (Van Der Merwe and Pepper, 2006). There are
varying results depending on the parameters used to identify obesity. The use of the
body mass index (BMI) has been found not to work in some ethnic groups but those
ethnic groups may be diagnosed as obese using the waist to hip ratio (Amoah, 2003).
Taking ethnicity to consideration in studying obesity is crucial and these studies have
been done in most countries. There are differences in response to environment X gene
interaction based on ethnicity. Some ethnic groups tend to respond more than others
to the environmental changes with different energy distribution accompanied by the
differences in expenditure.
 
 
 
 
6Extensive studies have been conducted for obesity in different fields that include
epidemiology, nutrition, genetics, and many more focus areas with the introduction of
proteomics which is still new. The role of genes in obesity has been studied in
animals as it is expanded in the following sections. Obesity studies in humans showed
that genes are not oriented the same way in humans as in animals which shifted the
focus to gene polymorphisms which answered quite a number of questions.
1.1.1 Prevalence and diagnosis of obesity
The global obesity prevalence has been reported to have reached epidemic proportion
for over a decade now. The increase in people that move from rural to urban areas has
risen dramatically as developing countries are advancing to technology  based
era of robotics and computers. Currently 300 million people worldwide can be
considered as obese, and due to the rising trend in obesity prevalence, this figure
could double by year 2025 if no action is taken against this threat (Flick et al.,
1977b, Formiguera and Canton, 2004). The prevalence of obesity has been shown to
be underestimated especially in Sub-Saharan Africa. The studies by Puoane et. al.,
2004 and Parker et. al., 1997 do not reflect the true situation of the impact of
obesity  in South Africa. The organizations that deal with statistics on obesity have
not been active enough in terms of keeping the updates of the obesity standings in
South Africa which is evidenced by the lack of most recent data on obesity epidemic.
 
 
 
 
7The awareness has been spread on the press releases regarding the obesity state in
South Africa. The figures below shows the published cases of obesity state in South
Africa which is spreading in all age groups.
A B
Figure 1.1: Images showing cases of obesity in South Africa as published by the press
The figure represents the cases as appeared on the newspaper where a toddler of 14 months of age was
reported to weigh as much as 31kg (Mahlangu, 2012) (A). An obese adult (B) was shown in a
different article (Laurence, 2012).
In the United States of America, 133.6 million (66%) adults are overweight or obese
with 63.3 million (31.4%) that are considered being obese (Cannon and Kumar,
2009b). This means US as country is facing more than 90% cases of weight
problems. Prevalence data in the United States of America is always available unlike
in other countries but that can be due to the availability of the resources to run the
studies towards the prevalence of obesity.
 
 
 
 
8Body mass index (BMI) is commonly used for obesity diagnosis. BMI is the ratio of
the weight (in kilograms) divided by height (in metres) squared: BMI = kg/m2 (Rippe
et al., 1998). BMI is accepted as a better estimate of body fatness and health risk than
body weight. There is a need to clarify that BMI is not a measure of body fatness but
obese people tend to have excess body fat. BMI in overweight range is less healthy
for most people, but in some cases may be acceptable for people who are muscular
and have less fat. The BMI of >25 kg/m2 is said to be for overweight individuals
while the BMI of >30 kg/m2 is considered to be obese (Leonhardt et al., 1990). The
World Health Organization classification of obesity is tabulated below to show more
categories (James, 2004).
Table 1.1: WHO classification of obesity
Classification BMI Risk of comorbidities
Underweight 18.5 low*
Normal range
Overweight
Pre-obese
18.5-24.9
≥25
25.0-29.9
Average
Increased
Obese class 1 30.0-34.9 Moderate
Obese class 2 35.0-39.9 Severe
Obese class3 40.0 Very severe
*increased risk of other clinical problems increased
 
 
 
 
9Waist hip ratio (WHR) has been used as a predictor of obesity in some studies. The
waist hip ratio is an index of body fat distribution which has been shown to be a
predictor of coronary heart disease. It appears to be a measure of central obesity
(Sosenko et al., 1990). The recommendations of using waist circumference cut points
of 40 inches (102cm) in men and 35 inches (88cm) in women to define central
obesity has been used successfully to define the risk association (Beydoun and Wang,
2008). BMI is still crucial in epidemiological and clinical diagnosis of obesity and the
WC is used to identify abdominal obesity.
1.1.2 Genetic and environmental causes of obesity
Obesity development has been associated with a number of factors. The obesity
research has evolved to focus to factors leading to obesity. In most cases it is the
combination of a lot which is now get presented as genetics x environment. This
shows a bigger picture but the physiological changes go deeper to understanding what
takes place during the change from a lean to an obese state. The excessive formation
of adipose tissue that is due to excessive differentiation of adipocytes and storage of
energy as fat is the most noted cause. The body homeostasis is the implicated process
in the body weight gain because with proper energy balance obesity is least expected.
Various organs contribute to energy homeostasis. A lot of processes take place in
different organs as a way of controlling energy in the body. This takes place
through energy storage or energy utilization. The organs that contribute to energy
homeostasis are shown in (Figure 1.2).
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There is an established communication of organs with the central nervous system
especially the hypothalamus for the energy homeostasis. Satiety signals that are
produced from gastrointestinal tract in response to the presence of food include gut
peptide cholecystokinin, bombesin, gastrin-releasing peptide, neuromedin B and
glucagon (Gale and Grant, 2004). Insulin and leptin modulate immediate peripheral
satiety signals. These hormones directly target the central nervous system and inhibit
food intake (Flick et al., 1977a, Gale et al., 2004). The figure shows that there are
receptors in the central nervous system for the hormones and peptides produced
peripherally which concludes the communication between peripheral organs with
CNS. The breakdown in the communication may lead to a defect in the control of
energy leading to the kick start of insulin resistance which leads to obesity and related
conditions.
 
 
 
 
Figure 1.2: Various organs that play a major role in energy homeostasis (Gale et al., 2004)
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The impact of diet to the development of obesity is very much noted. The definition
of obesity as a condition that results from energy imbalance is based on dietary
control. A challenge is to every individual to match the energy intake with the energy
expenditure to overcome diet induced obesity. The abundance of calorie-dense and
aggressive food marketing in mass media, supermarkets and restaurants, the large
portions of food served outside the home, promoted high calorie consumption
(Montague, 2003). This contributes to the increasing prevalence of obesity because
besides exceeding the recommended limit of energy intake people do less physical
activity to offset their consumption.
The content of food also contributes to the determination of energy that is consumed.
Research in both humans and animals suggests that high fat diets that are low in
complex carbohydrates promote obesity (Astrup and Finer, 2000). Fat contributes
9kcal/g compared to 4kcal/g for proteins and carbohydrates (CHO) leading to high
energy intake from eating high fat foods than would be when eating a similar quantity
of lower fat foods. Fat modifies the taste of food and in some people, it promotes
excessive intake. This is because of the weaker satiation effect from dietary fat than
CHOs, resulting in the over consumption of fat (Rolls and Rowe, 1979). Compared
with dietary fat, CHOs require additional energy expenditure for digestion,
assimilation and conversion to fat. Fat consumed need not be digested because of the
state that they are at but only a little energy is needed for their storage. This means
low energy in CHOs is also used for conversion and as a result the stored energy gets
reduced than would have been for fat.
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Carbohydrate intake contributes to the overall obesity development. There are
postulates around the use of high protein and low carbohydrates in the diet. Increased
calorie intake as CHOs has adverse physiological effects like increased insulin
secretion, promotion of fat deposition and rise in serum triglycerides levels. Diet
with low CHO can lead to a ketogenic  state  which has been hypothetically
related to appetite suppression. Diet high in protein preserves lean body mass
during weight loss. Protein compared to CHOs and fats is having highest
thermogenic effect resulting in increased energy expenditure for a similar intake. A
controversy has been raised by the role of CHO in soft drinks in producing obesity.
French et al., (2000) suggest the increase in the consumption of soft drinks may
contribute to the increased prevalence of obesity.
Dietary fats are the most water free source of energy for the body and are composed
of 98% triglycerides which supply approximately two-thirds of the cells total energy
requirement (Montague, 2011). Saturated fats have been proven to affect blood
cholesterol levels. Saturated fats that raise cholesterol include lauric, myristic and
palmitic acids which are found in butterfat, meat fat and vegetable oils that harden at
room temperature e.g. coconut, and palm kernel oils (Stone, 1996). Monounsaturated
fats also raise blood cholesterol, although not as potently as do saturated fats and they
may lower HDL cholesterol (Mensink et al., 1990). Polyunsaturated fatty acids
(PUFA) lower serum cholesterol (Grundy, 1990). Two kinds of PUFA are n-6 PUFA
and n-3 PUFA with sources of n-6 PUFA being seed oils such as corn, safflower, and
cottonseed which are rich in linoleic acid. The n-3 PUFA include fish oil and linoleic
acid, a plant source.
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Food processing has seen more refining of food and the reduction of the required
roughage. This is looked at as an improvement by the food industry. Food that is
eaten by most people in developed world lacks fiber. Fiber is crucial portion of every
diet because of the role that it plays in the process of digestion. Insoluble fiber
contributes by promoting regular bowel movements and soluble fiber helps lower
cholesterol (Kwiterovich, 1995). Rimm et al. (1996) reported that increased fiber
is associated with reduction in coronary artery disease (Rimm et al., 1996). That
study further revealed an inverse association between total fiber intake (mainly
vegetables, fruit, and cereal) and the risk of fatal and non-fatal myocardial infarction
that was independent of fat intake (Rimm et al., 1996).
Social aspects of life influences development of obesity. In South Africa there is an
increased rate of social gatherings where people eat more food of animal origin
compared to that of the plant origin. Restaurants also sell more meat than vegetables
as their core business. Fast food outlets are found in most corners of South Africa as
she continues to develop. Such a social behavior has long been reported in the US
which is the leading country in obesity where Morgan and Goungetas, (1986)
reported an increased snack consumption. The turnover in the work place setup has
seen more physical work being done by robotics and personnel sit the whole day in
front of computers. This alone gives a situation whereby the energy expenditure has
been reduced as the intake of energy increases. The more urbanized African
communities get the higher the rate of obesity and the less prudent their diets
become (Kruger et al., 2005, Puoane et al., 2002).
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Obesity has been studied based on biological, psychological and behavioural factors.
Looking at the factors as mentioned above does not fully explain the rapid growth in
obesity cases that has been witnessed in the past decades. There is growing agreement
among researchers and policy makers that the social and physical environment may
play an important role as well (Poortinga, 2006). Environments may be obesogenic in
the sense that they  promote caloric intake and/or discourage the expenditure of
energy. The study in US showed that there was an increase in usage of vehicle
through reports on an increase in miles of transportation done (Samimi et al., 2009).
In this study it was concluded that a 1% decrease in the use of automobiles can
decrease obesity by 0.4%. Residents of neighbourhood with high population density,
proximity to commercial destinations and good public transportation are more
physically active than residents of less walkable neighbourhoods often deemed
“surbuban” (Frank et al., 2007).
To make up for the environment impact on obesity development changing an
environment from obesogenic environment to an environment that promote energy
expenditure is required. Studies have proven that positive energy balance results in
accumulation of excess fat stored in the form of fat. The study that was conducted in
Australia showed that to support the extensive survey that was conducted in USA,
which found that the pervasive availability of vehicles, combined with heavy
advertising and urban and suburban designs that support the vehicles as the most
convenient transportation mode, is an important environmental influence on physical
activity levels (Hinde and Dixon, 2005).
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Obesity genetics has been studied for decades in both animals and humans (Fawcett
& Barroso, 2010). Studies on obesity managed to reveal a number of genes
associated with obesity to date (Harrera et al., 2011). In animals the mouse has been
widely studied genetically for obesity. There are five widely used monogenic mouse
models of human obesity; those are diabetes, obese, yellow, tubby and fat (Naggert et
al., 1997). Mice homozygous for the obese mutation displayed features of
hyperphagia leading to obesity and diabetes, inappropriately decreased energy
expenditure, reproduction deficiency and stunted growth. The product of cloning
obese gene was a protein leptin which itself has been studied extensively. Mice
carrying mutation at diabetes locus exhibit a very similar phenotype to obese mice
that studies suggested diabetes to be the receptor for leptin in the central nervous
system (CNS). This has been found to be the lack of the long form of leptin receptor
for the diabetes mouse leading to defects in the signalling across the blood brain
barrier. Dominant alleles (yellow) at the agouti locus lead to a complex phenotype
which includes maturity onset obesity, pigmentation defects, insulin resistance and
an increased frequency of tumors. Fat mice carry an autosomal recessive mutation
and display a range of abnormalities, including progressive adult onset obesity,
hyperinsulinaemia and infertility. The mutant allele of fat showed to be a missense
(serineproline) mutation in carboxypeptidase E (CPE). The tubby mouse has
an autosomal recessive mutation and displays a tripartite phenotype of blindness,
deafness and maturity onset obesity. These mice increase their intake gradually in
response in proportion. The mutations that were seen on mice do not reflect what is
happening in humans.
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The genetics of obesity has been studied in both humans and animals, which added to
the body of knowledge the rare monogenic forms of obesity and polymorphisms. The
uses of the information on genes showed to be dependent on the permissive
environment for the genes to be triggered and kick start the weight gain process.
Based on the previous studies available information on human genetics needs to be
acknowledged.
1.1.2.1 Diet as an environmental factor for studying obesity in rats
Rodents are a major tool to study conditions affecting humans due to the great
similarity and homology between the genomes of rodents and humans (Von Diemen,
2006). Outbred rat strains, which include Sprague Dowley and Wistar rat, are popular
strains to study obesity as they readily gain weight on high fat diets (Gadja, 2008).
Induction of obesity using diets depends on many factors including but not limited to
susceptibility of the rats to obesity development (Choi, et. al., 2010). Susceptibility
can be towards the sources of calories in the diet used e.g. high carbohydrate or high
fat diet. The high fat diets that are mostly used for laboratory animal research contain
more unsaturated fats such as lard, beef tallow or coconut oil and these diets are quite
capable of inducing obesity in susceptible strains (Gadja, 2008).
1.1.3 Behavioural, pharmacological and surgical treatment of obesity
Treatment of obesity has been given attention in many ways. There are various
approaches that are being used towards the treatment of obesity. The association of
obesity with energy imbalance has been revealed more than two decades ago. Sliming
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has  been  one of the approaches to  the prevention  of excess energy intake.  The
treatment of obesity can be grouped into categories; those are behavioural,
pharmacotherapy and surgical interventions.
The successful treatment of obesity  is marked by a preferential reduction of
abdominal fat accompanied by amelioration of obesity related health risks, an
improvement in quality of life and a reduction in mortality rate (Cannon and Kumar,
2009b). It is important to note that in most cases there is a higher failure to lose
weight for the people that already gained excess weight. For a less ambitious
approach goals can be set to reducing body weight and maintain lower body weight
over a long time. To make things bearable for the people that cannot lose weight their
goal can be to prevent further weight gain.
To date there is no medical treatment that promises to be successful in treatment of
obesity. While the treatment of obesity aims to achieve best results with less harm to
the patients none of the treatment strategies works without challenges. Behaviour
based treatment fails because of the response of the patients that is dominated by a
thought of obesity as a lifestyle than disease making them to have low self esteem
and reduced eager to respond to the disease. The required change that is expected by
patients when joining the behavioural change adds to their loss of faith in the therapy.
The pharmacotherapy came with lots of negativity to practitioners because of the side
effects involved. Most of the drugs used for obesity in the past were withdrawn
because of life threatening side effects. The invasiveness of the surgical therapy
makes a huge percentage of the obese community not to consider the treatment. Each
 
 
 
 
19
treatment will be discussed briefly in the following sections.
1.1.3.1 Behavioural therapy of obesity
Behavioural therapy is a method for systematically changing eating, exercise, or other
behaviours that are thought to contribute to or maintains obesity (Foreyt and
Poston, 1998). Behaviour therapy comprises self-monitoring (i.e. keeping food and
activity logs), stimulus control (i.e. controlling cues associated with eating), stress
management,   nutrition education,   slower eating habits,   problem solving,   the
rewarding of changes in behaviour, cognitive restructuring, social support, physical
activity and relapse prevention (Cannon and Kumar, 2009a). In the behavioural
treatment what has been of note in most studies is that one must not assign high odds
of success. Many researchers that did research on obesity treatment dating over two
decades ago until the present are humbled by obesity in that they realised that
it is difficult to maintain a new lower weight following a weight loss (Brownell,
2010).
The success of weight loss treatment depends on the structure, principles and
techniques used with the patient (Corbalán et al., 2007). Incorporation of
psychological well being to interventions needs to be part of every patient’s
program not just a mere weight loss. Individuals with improved self esteem and
body dissatisfaction have a higher likelihood of finishing among the successful
weight loss group, to an extent independently of their initial weight loss (Palmeira et
al., 2010). A typical behavioural program, incorporating a 1200 kcal/day diet,
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produces a weight loss of about 10% of initial body weight amongst the patients who
complete the treatment (Cooper and Fairburn, 2001). The study by Corbalan et. al.,
(2009) raised more parameters that contribute to failure of behavioural therapy. In
conclusion this study points out to the therapist ways to improve behavioural
programs by considering that losing motivation to lose weight, being prone to stress
related eating, being predisposed to eating when bored and thinking in black-and-
white are some of the barriers for losing weight. Also emphasized is the
encouragement of patients to record food intake and attending to group therapy.
1.1.3.2 Pharmacotherapy of obesity
Drugs that have been on the market prior to the 21st century include Dinitrophenol
which is having thermogenic action resulting from uncoupling of oxidation
phosphorylation from ATP formation. This drug was withdrawn from the market in
the 1930s due to death cases from multi-system side effects (Finer, 2002). Synthesis
of amphetamines followed the discovery of ephedrine from Chinese plant Ephedra
sinica. These drugs were used as stimulants but it became apparent that they also
suppress appetite and food   intake. Related drugs were   produced those are
phentermine, diethylpropion and mazindol all three acting by blocking re-uptake of
noradrenaline in hypothalamus neurones. Being stimulants some of the drugs with
longer half life they interfere with sleep and cause unpleasant state of arousal. All
three drugs were withdrawn in Europe but still available in other continents.
Fenfluramine emerged in the 1960s with dexfenfluramine in the 1980s.
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Pharmacotherapy in obesity led to discovery of a number of drugs that are partially
successful but their challenge lies in the complexity of obesity itself. Many attempts
have been made to correct metabolic disparity of the obesity condition, producing a
number of reagents including Sibutramine (appetite suppressor), Orlistat
(gastrointestinal lipid uptake inhibitor), and Fibrates (PPAR agonists) (Choi et al.,
2007). Orlistat and sibutramine were still on the market worldwide, until
thesuspension of the sibutramine‟s marketing authorizations by the European
Medicines Agency in January 2010 due to concerns that  it could lead to
increased risk of developing heart problems (Hsu et al., 2010).   The research in
pharmacotherapy is perpetually producing drugs and many of the drugs are already in
phase III of clinical trials. Remonabant, a drug that was developed to treat obesity
with mechanisms of action involving cannabinoid receptors in the central nervous
system and peripheral tissues (e.g. adipocytes), failed to win FDA approval and
was recently withdrawn from the market in Europe because of its serious psychiatric
adverse effects (Cannon and Kumar, 2009a).
1.1.3.3 Surgical therapy of obesity
Surgical treatment of obesity or bariatric surgery is a treatment option for morbidly
obese patients with BMI ≥ 40kg/m2 or a BMI ≥ 35 kg/m2 and significant obesity-
related comorbidities (Robertson, 2006). Procedures are categorised as restrictive or
malabsorptive. Restrictive surgery aims to reduce the volume eaten at each meal, but
does not alter the route ingested food takes through the gut e.g. gastric banding and
vertical band gastroplasty. Malabsorptive surgery will usually include a restrictive
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element but also includes surgical modification of the gastrointestinal tract to reduce
nutrient absorption, normally bypassing part of the small intestine. Gastric bypass and
duodenal switch are examples of malabsorptive surgery. Bariatric surgery is a highly
effective treatment approach that results in a reduction in BMI of 10 to 15 kg/m2 and
a mean weight loss of 20 to 40 kg (Cannon and Kumar, 2009a).
Currently, surgery offers the only viable treatment option with long-term weight loss
and maintenance for the morbidly obese (Miller, 2004). Surgical treatment of obesity
is proving to be the best and most effective means of preventing the life-threatening
complications and serious degenerative problems associated with morbid obesity. It is
always advised that the patients that go for bariatric surgery must be ready for
perioperation and postoperation. It is reported that bariatric surgery contributes to the
loss of fat mass with a much lower loss of fat free mass (Frige et al., 2009). In
addition to that there is a reduction in visceral fat more than subcutaneous fat. This
further improves glucose metabolism as it lowers blood glucose levels, insulin levels,
insulin resistance (HOMA index) and reduces prevalence of type 2 diabetes mellitus
and prevent its occurrence in obese subjects with impaired glucose tolerance (IGT)
(Buchwald et al., 2004, Pontiroli et al.,  2005). The need for the patient‟s
preparedness contributes the most because that helps in standing  the trauma of
surgery and playing along in terms of behaviour change for the effectiveness of the
procedure.
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1.2 Obesity as a risk factor for chronic diseases of lifestyle
Many diseases have been found to be associated with obesity. The development of
obesity has been associated with a variety of conditions including cancer, diabetes,
metabolic syndrome, sleep apnoea and other conditions that continue to be associated
with obesity. As obesity has long been defined as the accumulation of body fat the
association of obesity with fatty liver has been increasing for researchers and the
people in general. The accumulation of body fat has been associated with influx of fat
in the body that leads to the development of adipose depots in all the organs of the
body besides the adipose tissue. This is the increasing reason for the people to see the
fat intake as the main cause of the abnormality and uncontrollable situation for those
exposed to high fat diet and high caloric intake of any kind.
The prevalence of obesity-related health problems increases proportional as the BMI
and the duration of obesity increase. It is always advisable for the people that suffer
from co morbidities to reduce their body weight as a first step to resolve weight
related problems. Obesity is thought to be the leading risk factor for osteoarthritis of
the knee. As morbid obesity usually requires surgery many of the comorbidities
interfere with the anaesthesia. What have been of concern to anaesthetists are diabetes
and those diseases that are affecting the respiratory and cardiovascular systems.
Much co morbidities interrelate with each other as it is reported that the combination
of gastric hyperacidity and an increased gastric volume with sleep apnoea, snoring
and impaired upper airway reactivity, give rise to nocturnal micro aspiration. This
combination precipitates lower airway reactivity and symptoms of asthma.
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Comorbidities touch most of the medical issues orthopaedic, neurology, pulmonary,
gastrointestinal, gynaecology, endocrine, cardiovascular, psychology, skin, metabolic,
infectious, and oncology. Through this there is a chance of misdiagnosis and
underestimation of obesity to date.
1.2.1 Obesity as a risk factor for impaired glucose regulation
Impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) refer to the
levels of blood glucose concentration above the normal range but below those which
are diagnostic for diabetes (WHO, 1999). The two conditions are different in such a
way that they refer to the inability to bring glucose levels to normal post-prandially
and the other one refers to elevated fasting glucose levels in a fasting state. The
values of IFG are fasting plasma glucose concentration of 6.1 mmol/l or greater;
whole blood 5.6 mmol/l, but less than 7.0 mmol/l. If oral glucose tolerance test
(OGTT) is performed, some individuals with IFG will have IGT or diabetes, but this
cannot be determined without an OGTT. Previous studies, which have been carried
out mainly in middle-aged people, have shown, although not quite consistently, that
the deterioration in glucose tolerance is associated with at least positive family
history of diabetes, overall obesity, central distribution of body  fat, lack of
physical exercise, and elevated systolic or diastolic pressure (Hiltunen et al., 1997).
Studies also revealed the impaired regulation to be associated with brain atrophy and
neuropsychological deficit which were found in preliminary studies comparing obese
type 2 diabetic adolescents with obese non-diabetic adolescents (Messier et al.,
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2011). The link between cognition and glucoregulation appears to occur in a
continuum from impaired glucose tolerance to type 2 diabetes. Hyperinsulinaemia as
well as high fasting glucose in non-diabetic older people are also associated with
decreased cognitive function (Yau et al., 2010, Rolandsson et al., 2008). Impaired
glucose regulation is central to most of the metabolic conditions because it starts with
impaired regulation to conditions like diabetes and its complications that usually get
to be controlled in very painful ways e.g. amputations.
1.2.2 Obesity as a risk factor for diabetes
Diabetes  is one  of  the most costly and burdensome  diseases in the  world with
increasing epidemic proportions worldwide. Diabetes mellitus represents a group of
diseases of heterogeneous aetiology, characterized by chronic hyperglycaemia and
other metabolic abnormalities, which are due to deficiency of insulin effect (Kuzuya
et al., 2002). Diabetes is the leading cause of renal failure in many populations in
both developed and developing countries. Lower limb amputations are at least 10
times more common in people with diabetes than in non-diabetic individuals in
developed countries; more than half of all non-traumatic lower limb amputations are
due to diabetes (WHO, 2011).
The relationship between obesity and diabetes has long been raised in the research
community. The challenge in the two states is that not all obese people are diabetic
and not all diabetics are obese either. Obesity has been proven to lead to insulin
resistance, insulin resistance leading to impaired glucose regulation that eventually
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results to type 2 diabetes mellitus (T2DM).
1.2.3 Obesity as a risk factor for Coronary Heart Diseases and Hypertension
Heart attacks have been a concern due to the rise in number of people dying of heart
attacks. Coronary heart disease (CHD) is a narrowing of the small blood vessels that
supply blood and oxygen to the heart. Coronary artery disease is the other term for
CHD. Atherosclerosis which occurs as the fatty material and other substances form a
plaque build up on the walls of the arteries. This causes the narrowing of the coronary
arteries leading to a slow down to a stop of the blood flow to the heart. People with
CHD can experience chest pain (stable angina), shortness of breath, heart attack and
other symptoms usually for active individuals.
Coronary heart diseases have been found to be influenced by various factors. These
include dietary fat, smoking, alcohol consumption and lack of exercise  (Talmud,
2007). Low density lipoprotein (LDL) particles promote atherosclerosis by entering
the artery wall, becoming oxidized and subsequently being ingested by macrophages,
to create rich foam cells, which develop to atherosclerotic plaques (Cromwell, 2007).
Weight loss, even of 5-10% of total body weight has beneficial effects regarding
coronary   heart disease risk factors; total cholesterol, LDL cholesterol and
triglycerides levels are decreased HDL cholesterol levels are increased, blood
pressure levels are reduced and glucose metabolism is improved (Kastorini et al.,
2010). Mechanism by which cigarette smoking exerts its cardiovascular damaging
effect is not clearly delineated (Chrysant, 2011). The most plausible mechanisms
 
 
 
 
27
include, lipid oxidation, inflammation and thrombosis, with lipid oxidation being the
most dominant (Ambrose and Barua, 2004). Heavy alcohol consumption has been
related to increased risk of cardiovascular disease, whereas moderate alcohol intake
has been associated with a cardio-protective effect (Burazeri and Kark). Based on the
above  the American Heart Association (AHA) recommends that if alcoholic
beverages are consumed, they should be limited to no more than 2 drinks per day for
men and 1 drink per day for women, ideally with meals (Bhupathiraju and Tucker).
Hypertension (HTN) is a multi-factorial, polygenic disease that involves complex
interactions between genetically determined homeostatic control mechanisms and
environmental factors (Lerman et al., 2005). The diagnosis of HTN is based on
multiple conventional   blood pressure (BP) measurements taken on separate
occasions, in the sitting position by  the use of mercury  sphygmomanometer or
another calibrated device and is universally defined as a systolic BP of 140 mmHg or
higher, a systolic BP of 90 mmHg or higher, or both (Fagard). Approximately 95%
of hypertensive patients have essential or primary HTN, which is a multi-factorial
disease, resulting from an interaction between genetic and lifestyle/environment
factors. These include being overweight, high salt intake, excessive alcohol
consumption and physical inactivity.
Obesity and systemic arterial hypertension are two conditions that have been directly
related. Thus, the incidence of hypertension in the obese population is greater than
that in a non obese population (Ventura et al., 1992). Visceral obesity promotes an
increase in the availability of free fatty acids, potentially mediated through the
 
 
 
 
28
hydrolysis of stored adipocyte triglyceride by  a range of lipases, including
triglyceride lipase, lipoprotein lipase, hormone-sensitive lipase and endothelial lipase
in adipose tissue (Chapman and Sposito, 2008). The accumulation of circulating free
fatty acids lead to triglyceride accumulation in muscle and liver (in the form of
hepatic steatosis) and to hyperglyceridaemia subsequent to enhanced hepatic
production of VLDL. The rise in blood pressure may also be mediated by enhanced
release of free fatty acids from the adipose tissue of obese patients in various
mechanisms. These include the activation of 1-adrenoceptor-mediated
vasoconstriction, attenuation of endothelial production of NO with induction of
oxidative stress and inhibition of insulin-mediated vasodilation (Egan et al., 2001,
Sarafidis and Bakris, 2006).
1.2.4 Obesity as a risk factor for sleep apnea
Sleep apnea is a prevalent disorder characterized by loud snoring and daytime
sleepiness. Fat infiltration to the upper airway has been shown to be related to the
prevalence of obstructive sleep apnea, and impairment of the ventilatory drive, to
central sleep apnea (Ramadan et al., 2006). Repetitive cessation of airflow associated
with arousal and hypoxemia has been seen in sleep apnea, further more there is an
association of sleep apnea with morbidity and mortality  from stroke and heart
diseases (Li et al., 2010). Studies have been done to establish the association of
obesity and disorders like insulin resistance and impaired control of breathing
(Ramadan et al., 2006). Currently there is a difficulty in distinguishing the respective
role of fat infiltration in the upper airway and impairment of ventilatory drive in
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generation of sleep apnea because the disorder is diagnosed late in its course (Mehra
and Redline, 2008).
Because of frequent co aggregation of obesity and sleep apnea it is often difficult to
discern which health or pathophysiological effects are attributable to one or the other
condition, and which effects may reflect additive or synergistic effects (Li et. al.,
2010). Obesity has been stated to be a pro-inflammatory disorder for a long time
which is something that has been reported for sleep apnea due to hypoxia/hyperoxia
and sleep fragmentation which oftentimes cause or exacerbates pro-inflammatory
states on sympathetic hyper reactivity or oxidative stress. Common pathways for both
conditions include adipose tissue production of pro-inflammatory cytokines and
chemokines such as TNF-, IL-6, and leptin with reduction in adiponectin levels.
Animal studies especially rodents demonstrated that background levels of obesity
influence metabolic responses to intermittent hypoxemia. In humans pro-
inflammatory responses to sleep apnea are also influenced by obesity and conversely
obesity related effects on inflammation and cardiopulmonary disease are influenced
by coexisting sleep apnea.
1.3 Metabolic syndrome
Obesity is a key component of metabolic syndrome, which is characterized by
increased visceral adipose tissue, peripheral insulin resistance, hyperlipidemia and
elevated blood pressure (Yan et al., 2007). When high blood pressure, dyslipidaemia
and insulin resistance present together, and are in turn associated with hyperglycemia
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and visceral obesity, they are collectively identified as the metabolic syndrome
(Chapman and Sposito, 2008). Indeed this syndrome is characterized by a risk factor
constellation that predisposes patients to the accelerated development of
atherosclerosis and CVD (Gami et al., 2007). Table 4 shows the guidelines from the
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)
to define the metabolic syndrome on the basis of a combination of 3 or more key
criteria among a series of 5 (Expert Panel on Detection and Adults, 2001).
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Table1. 2: Features of commonly used definitions of metabolic syndrome (Expert Panel on Detection and Adults, 2001)
Defining level
WHO (WHO consultation,
1999). Impaired glucose
tolerance glucose tolerance
or diabetes and/ or insulin
resistance and two other
factors
EGIR (Balkau and Charles,
1999). Presence of fasting
hyperinsulinemia (highest
25%) and two factors
ATP-III (NECP Expert
Panel on Detection, 2001).
Three or more of the
following factors (TAGs
and HDL counted
separately)
IDF, Central obesity and
two other factors
Central obesity WHR ≥ 0.9 (men), 0.85
(women) and/ or BMI > 30
kg/m2
Waist ≥ 94 cm (men), ≥ 80
cm (women)
Waist ≥ 102 cm (men), ≥
88 cm (women)
Waist > 94 cm (European
men), > 90 cm (Asian
men), > 80 cm (women)
Blood pressure (mmHg) ≥ 140/90 ≥ 140/90 or treated for
hypertension
> 130/85 or treated for
hypertension
≥ 130 SBP or ≥ 85 DBP or
treated for hypertension
Dyslipidemia (mmol/l) TAGs ≥ 1.7, HDL < 0.9
(men), < 1.0 (women)
TAG ≥ 2.0 or HDL-
cholesterol < 1.0 or treated
for dyslipidemia
TAGs ≥ 1.7, HDL-
cholesterol: < 1.0 (men), <
1.3 (women)
TAGs ≥ 1.7, HDL-
cholesterol, < 1.04 (men),
< 1.29 (women)
Dysglycaemia (mmol/l) Fasting glucose ≥ 1.6 and/
or 2h post-challenge
glucose ≥ 7.8 on diabetes
Fasting plasma glucose >
1.6, but non-diabetes
Fasting plasma glucose ≥
6.1
Fasting glucose ≥ 5.6 or
previous diagnosis of
impaired tolerance or
diabetes
Insulin resistance Glucose uptake during
hyperinsulinemic-
euglycaemic clamp in
lowest quartile for
population
Presence of fasting
hyperinsulinaemia (i.e.
among the highest 25% of
the non-diabetic
population)
Not applicable Not applicable
Other factors WHO (WHO consultation,
1999). Impaired glucose
tolerance or diabetes and/
or insulin resistance and
other factors
EGIR (Balkau and Charles,
1999). Presence of fasting
hyperinsulinemia (highest
25%) and two other factors
Microalbuminuria (urinary
albumin excretion > 20
µg/min or albumin/
creatinine ratio > 30 mg/g
None
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1.3.1 Metabolic syndrome and controversy associated with the syndrome
There has been a differing of ideas regarding metabolic syndrome. The definitions of
metabolic syndrome can differ as shown in table showing the definitions from ATPIII
and WHO. Although including similar parameters but the cut off points are not the
same. A review into metabolic syndrome highlighted a concern on fundamental,
clinically important and critically missing information about the metabolic syndrome
to warrant a more serious examination of whether medical science is doing any good
by drawing attention to and labelling millions of people with a presumed disease that
does not stand on firm ground (Kahn et al., 2005). It is critical to mention that mostly
the syndromes will never be put at the forefront because it is not the entire syndrome
that gets identified as morbid but the individual risk factors and that causes a lot of
debate around recognition of the syndromes and metabolic syndrome is not an
exception.
Metabolic syndrome is a concept that has been slowly proving to be useful based on
the studies that showed the likeliness of predicting the future development of
cardiovascular disease/ diabetes (Aguilar-Salinas et al., 2009). This comes from a
series of definitions that has been used by various organizations to explain the
syndrome. The initial definition of the syndrome was given by Dr Reaven in the
Banting lecture that was published in 1998 where he postulated that insulin resistance
and its compensatory insulinemia predisposed patients to hypertension,
hyperlipidaemia and diabetes and thus was the underlying cause of much CVD
referring to the condition as insulin resistance syndrome (Kahn et al., 2005). The
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improvement in a quest to utilize the concept towards prediction and prevention of
morbid outcomes has graduated it to metabolic syndrome (MetS) (Bruce and Byrne,
2009). To date there is still a debate as to who is likely to develop the syndrome and
there is still a lack of the tailor made diagnostic criteria for certain people since
variations have been found to be dependent on parameters like race, age, ethnicity,
etc.
1.3.2 Obesity as a component of the metabolic syndrome
The recognition of abdominal obesity as the most prevalent clinically measurable
entity of the metabolic syndrome is one key advance of the concept (Després et al.,
2008). In the 21st century the research has been focusing on the lifestyle diseases and
the concern that is brought by the clustering of diseases. The then known as the adult
onset diabetes has been noticed in children of late. Obesity, which is the most
common cause of insulin resistance in children is also associated with dyslipidemia,
type 2 diabetes and long term vascular complications (Weiss et al., 2004). This might
explain the rise in obesity prevalence in children and the rise in type 2 diabetes in
adolescents and children.
The association of obesity with metabolic syndrome is being shown diagrammatically
in Figure 1.2 illustrating the possible correlates (A) of insulin resistance often found
among individuals with excess visceral/ectopic fat. Panel B emphasizes the notion
that the syndrome X/insulin resistance syndrome concept was based on
pathophysiological considerations, whereas panel C highlights the fact that NCEP
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ATP III and IDF metabolic syndrome is an entity identified by the presence of simple
screening tools (Després et al., 2008). Weight loss has been proven to improve the
insulin resistance which is the component of the metabolic syndrome with diet and
physical activity still at the forefront in achieving weight loss. The availability of
food guides like the DASH diet and the US Department of Agriculture MyPyramid
are designed to integrate sound dietary recommendations into a healthful way to eat
for life (Hollander and Mechanick, 2008).
Figure 1.3: Simplified Metabolic Syndrome model taken from (Després et al., 2008)
1.3.3 Adipocytokines associated with metabolic syndrome
Identification of metabolic syndrome association with obesity has brought into light
the increase in adipokines in the body system. Adipose tissue secretes a range of
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peptide and protein hormones  named adipokines implicated  in the  regulation of
energy metabolism, and it is also a great source of inflammatory cytokines that
participate in obesity related metabolism dysregulation (Roca-Rivada et al., 2011).
Such adipokines include adiponectin, leptin, resistin, tumour necrosis factor (TNF)-α,
plasminogen activator inhibitor-1 (PAI-1) and interleukin (IL)-6 (Rolland et al.,
2011). Adiponectin increases fatty acid oxidation and reduces the synthesis of
glucose in the liver. Ablation of the adiponectin gene has no dramatic effect on
knock-out on a normal diet, but when places on a high-fat/sucrose diet they develop
severe insulin resistance and exhibit lipid accumulation in muscles (Lago et al.,
2007b). This may explain the reduction in adiponectin levels for morbidly obese
individuals (Oh et al., 2007).
Leptin suppresses food intake and increases energy expenditure, decreasing in fasting
state and increasing after eating (Hallikainen et al., 2007). Adipokines, which are
directly produced by adipocytes or adipose tissue macrophages, induce a low-grade
chronic inflammatory state that could play a central role in obesity related
cardiovascular complications and insulin resistance (Antuna-Puente et al., 2008). It is
already raised and agreed that the adipose tissue have a cross talk with other organs
and this interaction is leading to energy regulation. The defect in the adipocytokine
production can be dangerous to the body through failure in the communication of
adipose tissue to the relevant organs for homeostasis resulting in states like insulin
resistance.
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1.4 Adiposopathy
Adiposopathy (“sick fat”) is defined as pathogenic adipose tissue that is promoted by
positive caloric balance, increased energy storage and sedentary life cycle in
genetically and environmentally susceptible individuals that may directly promote
CVD and may cause or worsen metabolic disease (Bays, 2011). The term
adiposopathy arose from decades of adipose tissue scientific research and
acknowledgement of the importance of central adiposity by major scientific
organizations. The theory that white adipose tissue (WAT) could be an active
contributor to the whole-body  homeostasis rather than just a fat depot became
tangible with the discovery of leptin in 1994 (Lago et al., 2007a). Since then a lot of
adipokines have been identified that are adipose tissue secreted adipokines as shown
in table 1 with the risks associated with them.
Obesity alone does not always result in clinical metabolic disease, and not all patients
with these metabolic diseases are overweight (Bays et al., 2005). Since the
identification of adipose tissue as an endocrine organ, the defects in the adipose tissue
have been associated with a lot of disorders including metabolic disorders. During the
positive caloric balance adiposopathy may be promoted by impaired adipogenesis,
pathogenic fat distribution, impaired nutrient metabolism, abnormal adipose tissue
factor activity, increased inflammation and dysfunctional „cross-talk‟ or pathological
interactions with other body organ systems (Bays et al., 2006). The changes at the
adopokine level require the in depth analysis of molecules involved. Proteomics as
used in our study maybe the approach that can identify not only the changes during
the obesity development but it may also reveal the adiposopathy related changes
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which will be useful in intervening on time before worse metabolic diseases kick
start.
1.4.1 Adiposopathy diagnosis
As explained above adiposopathy is sick fat in simple terms. The fat pathogenesis is
not dependent on the amount of fat. Currently there is no diagnosis for adiposopathy
because there is currently no guarantee that the physical parameters that are used for
diagnosing obesity for example can be used to predict the well being of the fat tissue.
Just as there is a great variance in functionality and dysfunctionality of adipose tissue,
further to that there is a variance in distribution of body fat among populations, and
adipose tissue function and distribution are related (Bays et al., 2005).
1.4.2 Major and minor criteria used to identify adiposopathy
The complications in the metabolic disorders research is due to the clustering of
factors that contribute to deadly conditions in a long run. Adiposopathy has been
identified to be exacerbated by fat accumulation (adiposity) and sedentary lifestyle in
genetically susceptible individuals (Bays and Dujovne, 2006). The argument is raised
by the increase of people that get excessive fat related metabolic disorders (EFRMD)
beyond addressing adiposity and obesity. This gives an indication that the state of the
adipose tissue itself needs to be taken into consideration as Bay, Abate, et al., 2005
mentioned that adipose tissue functioning needs to be looked at as well (Bays, 2005).
Adiposopathy can be identified taking into consideration a lot of criteria because
unlike fat accumulation and obesity but sick fat can be identified with more than just
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physical parameters. Major criteria consist mostly of major parameter and the minor
criteria are mostly the blood chemistry which is not usually looked at as shown in
Table 1.3. The in depth details on criteria won’t be touched in this thesis because
the table is touching on the proposed idea. Adiposopathy concept is not fully accepted
as yet but it will be able to shed light into why the people respond differently into diet
as the time goes. Proteomics will be an enhancer also for the adiposopathy concept
but this will be seen on the outcomes of the studies in diets and response like the
current study.
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Table 1.3: Proposed diagnostic criteria for the diagnosis of adiposopathy (Bays et al., 2005)
Major Criteria Minor Criteria
1.   Adiposity
 Body mass index (BMI) ≥ 30kg/m2 or
 Waist circumference > 102cm (>40in) in
men, or > 88cm (35in) in women or
 Waist:hip ratio > 0.9 in men, or > 0.85 in
women
2.   Abnormalities in glucose metabolism
 Fasting glucose blood levels ≥ 100mg/dl
(6.0mmol/l) or
 1h post oral 75g glucose load blood glucose
level ≥ 140mg/dl (7.8mmol/l) or
1.   Microalbuminuria
 Urinary albumin excretion rate > 20µg/min
or
 Albumin:creatinine ratio ≥ 30mg/g
2.   Onset of androgenemia in women; especially with
signs and symptoms of polycystic ovarian syndrome
 Elevated total testosterone or DHAES in
women, and possibly an increase in prolactin
levels
3.   Hepatosteatosis
 Otherwise unexplained elevated hepatic
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 Use of anti-diabetes drug treatment in Type 2
diabetes
3. Hypertension
 Systolic blood pressure ≥ 130mm/Hg or
diastolic blood pressure ≥ 140mm/Hg or
 Use of antihypertensive drug treatment for
high blood pressure
4. Dyslipidemia
 Fasting triglycerides level > 150mg/dl
(>1.7mmol/l) or
 Fasting HDL-C level < 40mg/dl
(<1.0mmol/l) in men or < 50mg/dl (<
1.3mmol/l) in women or
 Use of lipid-altering drug treatment of high
triglycerides or low HDL-C levels
transaminases, possibly with hepatic imaging
revealing findings consistent with fatty liver
4. Hypercoagulable state
 Otherwise unexplained thrombotic clinical
event in patients with elevated BMI, with
possibly an increase in plasminogen
activator inhibitor (PAI-I)
5.   Abnormalities of lipoprotein particle size and
subclass distribution
 Decreased LDL particle size with increased
prevalence of “pattern B”
6.   Hormone abnormalities of fat cell dysfunction
 Elevated fasting insulin levels, and or
decreased adiponectin levels or
 Elevated insulin/leptin to adiponectin ratio
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7.   Metabolic markers of fat cell dysfunction
 Elevated fasting or postprandial free fatty
acid levels
8. Inflammatory markers of fat cell dysfunction
 Elevated cytokine production (tumor necrosis
factor and/or interleukin-6), with elevated C-
reactive protein
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1.4.3 Adiposopathy treatment
The use of therapies that treat individual pathologic components that collectively
constitute adiposopathy can aid in improving the functioning of the adiposopathic fat
cells and tissue thereof (Bays et al., 2006). Weight loss through dietary interventions,
regular physical exercise and some pharmacologic agents can improve fat function.
PPAR gamma agonists have been said to increase the recruitment of new functional
and healthy fat, causing apoptosis of “sick fat” or dysfunctional fat, and increasing
the capacity of existing fat. Antidiabetes drugs may also improve glucose metabolism
and thus improve the hyperglycaemia consequences of adiposopathy (Bays, et al.,
2005). Current antiobesity agents such as orlistat and sibutramine have both been
shown to reduce body weight and also improve many metabolic abnormalities of
glucose and lipid metabolism that are otherwise associated with increased CHD risk
(Bays., 2004).
Bariatric surgery is also said to improve the adipose tissue endocrine and immune
response which is due to reduction in adipocyte size and a reduction in visceral
adiposity (Bays, 2009). Weight loss seems to be showing positive results that are in
line with adipocyte lifecycle hypothesis. The hypothesis states that the metabolic
properties of an adipocyte vary predictably during its lifecycle. As an adipocyte
matures, it accumulates triacylglycerol and becomes larger; that the rates of
triacylglycerol synthesis and lipolysis are matched within adipocyte and that larger
adipocyte, in general, have greater rates of triacylglycerol synthesis and concurrently,
greater rates of lipolysis and therefore, larger adipocytes have greater rates of
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transmembrane fatty acid flux, and that secretion of cytokines can also be related to
adipocyte size with larger adipocytes having a more unfavourable profile of cytokine
secretion than smaller adipocytes (Smith et al., 2006). The hypothesis points out the
defects that takes place in the adipocytes and adipose tissue that need to be corrected
and hence the focus of current therapy of obesity that aims at not just losing weight
but also to rectify the adipose tissue functioning.  Adiposopathy treatment is not
officially accepted as the concept is still getting introduced.
1.4.4 Research on adiposopathy and the future possibility of considering it as a
disease
The function of adipose tissue as an endocrine organ is proven by many studies. A
crosstalk between the organs is now being studied to further understand the problem
that leads to the increase in metabolic diseases. Adipose tissue is already spotted to be
the target for novel therapies (Klein et al., 2006). The adipose tissue performs three
main functions which are the secretion of adipocyte-derived hormones (adipokines),
energy dissipation/thermogenesis, and energy storage.  The organs that have been
given attention when it comes to metabolic disease have been organs either than
adipose tissue. There is a mounting evidence that adiposopathy plays a role in
metabolic disease. An emerging concept in treatment of obesity states that the
development of antiobesity agents must not only reduce fat mass (adiposity) but also
correct fat dysfunction (adiposopathy) (Bays, 2004, Scheen, 2008).
The adipose tissue produces adipokines that perform functions in the body and the
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disturbance in the functionality of such adipokines may cause a problem to the body.
It is known that the blood flow in gluteal adipose tissue is much lower than that in the
abdominal adipose tissue (Tan et al., 2004). Adiposopathy acknowledges that when
positive caloric balance leads to adipocyte hypertrophy and visceral adiposity, then
this may lead to pathogenic adipose tissue metabolic and immune response that
promote metabolic disease (Bays et al., 2008). This then try to breach the gap that is
created by the lack of explanation of why some obese people are metabolically
healthy? This can be related to the fat tissue being able to perform all the functions
listed above to the necessary expectation by the body. Because research is on in
various research avenues on adipose tissue the answers that arise from the research
will enhance the chances of accepting adiposopathy as a disease. Facts are slowly
piling up pointing at the contribution of sick fat in metabolic diseases which will see
adiposopathy reducing late intervention because of the criteria that is currently used
of using parameters like BMI to determine the need for treatment.
1.5 Advances in obesity research through genomics, proteomics and bioinformatics
Genomics is the study  of all the genes and their functions. The pharmaceutical
industry embraced genomics as a source of drug targets for decades now. There has
been well established source of genomic information that came from long started
studies of genes. The human genome project is the study that is influenced by the
information that has been obtained from single gene studies. There has been a strong
feeling about the break through that will come with full gene mapping leading to the
completion of human genome project in 2003.
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The success in genomics led to the birth of the other field that focused on studying all
the proteins that are a result of the genome called proteomics. Proteomics promises to
be the answer to the challenges that comes from the changes at protein level that
shapes the phenotype of most of the organisms. The powerful and robust approach in
proteomics  has seen  the evolution of  proteomics  from gel based to gel free
proteomics and the discovery of the stains that are useful in identifying the post
translational modifications which are role players in the changing of the phenotype.
Both proteomics and genomics generate a lot of data in a short space of time and the
storage of data and the utilization of such data will need proper and centralized
method for easy accessibility of such data to anyone in need of such data.
Bioinformatics has proven to be a powerful tool in data storage, acquisition, and
utilization towards addressing the problems encountered by the research community.
The information that is available through search engines and databases currently
covers most of the known information and the body of knowledge is not on a stand
still. The use of bioinformatics in research saves time that would be required for an
individual to search for the information that is available. When information is placed
in a central location it becomes easier for research community to access. The obtained
information remains to be utilized in a beneficial manner to address the problems
encountered.
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1.5.1 Application of genomics in obesity research
Genomics contributed a lot in the understanding of obesity. In 2004 the overall genes,
markers and chromosomal regions that were associated or linked with human obesity
phenotype were >600 (Perusse et al., 2005). These were evidence from single gene
mutation obesity cases, Mendelian disorders exhibiting obesity, quantitative trait loci
(QTLs) from animal cross breeding experiments, association studies with candidate
genes and linkages from genome scans. The focus in leptin-melanocortin pathway as
a target for pharmacological intervention in patients with severe obesity turned out to
be effective. The best illustration is certainly the case of a child with congenital leptin
deficiency who was treated with subcutaneous injections of recombinant human
leptin, leading to the correction of all the phenotypic abnormalities seen in this patient
(Choquet and Meyre, 2010).
Single-gene defects causing obesity are rare in humans, with affected individuals
suffering uncontrollable hunger and develop severe obesity at a young age (Wilding,
2003). The research in single genes managed to identify the situations associated with
genes in order to be able to prioritise the gene that might be contributing to obesity
(Figure 1.2). In the figure the condition that is associated with a defect in the gene
which is usually due to mutation in that particular gene is listed. This knowledge of
such conditions makes things easier for clinical applications of accumulated
knowledge in genomics in prioritizing the gene that need to be sequenced first based
on the properties seen in the patient. The monogenic obesity cases are rarely taking
place with the majority of obesity cases being polygenic. Polygenic obesity is
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commonly taking place in humans and this is challenging because it forms a cluster
of conditions that are difficult to address. While acknowledging the contribution of
genomics proteomics emerged to push the research a step further and the details on
proteomics impact will be discussed in the next section.
Table 1.4: Figure 1.4: Monogenic mutations associated with obesity (Wilding, 2003)
The figure shows the conditions and the single genes that are associated with their
alterations. The defect in leptin and leptin receptor genes (LEP and LEPR) are
associated with low leptin circulation, the defects may cause the reduction in
circulating leptin or the reduction in effectiveness of leptin when the receptors are not
fully functional. These effects can lead to development of obesity at childhood and
hypothyroidism. POMC gene monogenic defect can lead to hypoadrenalism,
 
 
 
 
51
jaundice, pale   skin, red hair and hypoglycaemia. On the other hand the
hypoglycaemia and/or intestinal dysfunction can be  the indication of  monogenic
effect of PCSK1. The development to high/tall stature indicates the defect in the
MC4R gene in contrast to delays in development that is seen in most cases when
there are monogenic defects associated with SIM 1, BDNF and/or NTRK2.
1.5.2 Application of proteomics in obesity research
1.5.2.1 Proteomics
Proteomics is defined as the analysis of the proteome, which is a complement of
proteins in cells, tissue, organs, and physiological fluids as well as their interactions
(Wang et al., 2011). Proteomics research embraces two contrasting   but
complementary strategies, those are cell-mapping proteomics, which aims to define
protein-protein interactions to build a picture of the complex networks that constitute
intracellular signalling pathways and the second strategy, is protein expression which
is based on the monitoring of global expression of large numbers proteins within a
cell type or tissue, and quantitatively identifies how patterns of expression change in
different circumstances (Simpson  2001). In addition  to  the above mentioned
strategies there is also a need to know the structures of proteins in order to understand
more and that is achieved using the so called structural proteomics which is the third
proteomics strategy.
Proteomics employs 2D-PAGE and various chromatography techniques for
separation of proteins (2) and soft ionization techniques, matrix-assisted laser
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desorption ionization (MALDI) and electro-spray ionization to vaporize peptides and
proteins enabling their analysis using mass spectrometry (MS) (1). Separation of
ionized peptides or proteins in the high vacuum of the MS is based on the differences
in their mass-to-charge (m/z) ratios, with time-of-flight (TOF) and electric ion trap as
major mass-selective analyzers in MALDI and ESI instruments, respectively (Wang,
2006). The approach of the current study was based on expression proteomics using
the gel  protein separation and  MALDI MS for analysis;  therefore the following
sections of this literature review will give details on the approaches as employed in
this study.
1.5.2.2 The use of 2D PAGE for separation of proteins
Two-dimensional polyacrylamide gel electrophoresis (2D PAGE) separates
thousands of proteins within a sample by their isoelectric points (pI) in the first
dimension and their molecular weight in the second (Wu et al., 2009). This method
was introduced in 1975 by O Farrell to separate hundreds of cellular proteins under
denaturing conditions (Issaq and Veenstra, 2008a). First dimension separation
evolved from being performed in plastic or glass tubes where by the protein was run
in the capillary tube and removed after running for second dimension as gel rods. An
introduction of immobilized pH gradients (IPGs) (Bjellqvist et al., 1982) improved
the resolution and the reproducibility which was not there before the introduction of
IPGs. Narrow IPG strips allowed a larger number of proteins to be separated than had
been possible with standard 2D PAGE because a narrower pH range was spread out
over a greater physical distance (Hoving et al., 2000).
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Advantage of using 2D PAGE is in the resolving many proteins at a go. What is a
challenge is the between gel variation that makes it difficult to compare the protein
from two different gels. The introduction of two dimensional difference gel
electrophoresis (2D-DIGE) overcame the limitations of 2D PAGE by allowing up to
three distinct protein mixtures to be separated within a single 2D PAGE (Unlu et al.,
1997). The 2D DIGE samples are tagged with dyes that bind to proteins prior to
running them on a 2D PAGE. The staining and visualization of proteins are covered
in the following section.
1.5.2.3 Detection of proteins in a 2D PAGE
Detection of proteins from the 2D PAGE is achieved using various staining methods
with the most popular being Coomassie brilliant blue (CBB). CBB methods found
widespread use for its low cost, ease of use and compatibility with most subsequent
protein analysis and characterization methods such as MS (Gorg, 2007). Silver
staining also gained popularity because of its sensitivity (in very low range), because
it can be achieved with simple and cheap laboratory reagents, and because it does not
require complicated and expensive hardware for the readout (Chevallet et al., 2006).
The uses of aldehyde-based fixatives/sensitizers are the most sensitive ones, but
prevent subsequent protein analysis like MS due   to protein cross-linkage
(Westermeier and Marouga, 2005). Omission of aldehyde in fixatives and in the
subsequent gel impregnating buffers (except in the developer), microchemical
characterization by peptide mass fingerprinting (PMF) is possible, however at the
 
 
 
 
54
expense of sensitivity (Gorg, 2007).
Fluorescent-based protein detection methods have recently surpassed conventional
technologies such as colloidal Coomassie blue and silver staining in terms of
quantitative accuracy, detection sensitivity and compatibility   with modern
downstream protein identification and characterization procedures such as MS
(Wayne F, 2002). Two major approaches for the fluorescent detections of proteins are
used currently, there are i) covalent derivatization of proteins with fluorophores prior
to IEF, and ii) post-electrophoretic protein staining by intercalation of fluorophores
into the SDS micelles coating the proteins, or direct electrostatic interaction with the
proteins (Gorg, 2007). Cyanine based dies are an example of pre-electrophoretic
fluorescent labels that react with lysyl residues. The most prominent example of
fluorescent dye that stains the proteins after electrophoretic separation has been
completed is the ruthenium-based dye SYPRO Ruby (Berggren et al., 2002).
Commercially there are a lot of stains available for all the categories mentioned above
but they won’t be covered in this review.
1.5.2.3.1 Mass spectrometry
Mass spectrometry has improved from an invention that is almost a hundred years
now by British Physicist JJ Thomson who invented the first mass spectrometer or
“parabole spectrograph” as it was known at that time (Marchetti-Deschmann and
Allmaier, 2011). Currently the technique is useful in various disciplines including
chemistry, biochemistry, and structural biology. Mass spectrometer is consisting of
three parts those are ion source, mass/charge (m/z) analyzer and detector. The sample
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is getting analysed in the fragmented form. There are other mass spectrometers that
further fragment the fragments like tandem MS or MS/MS. Fragments get ionized
and the detected for the output of data. Ionization sources are discussed in the
following sections.
1.5.2.3.2 Ion sources
The creation of intact molecular ions enables accurate measurements of molecular
weight. The electrospray ionization (ESI) and matrix assisted laser
desorption/ionization (MALDI) techniques revolutionized the analysis of
biomolecules. Among desorption ionization techniques MALDI is the most
appropriate for really high mass (≥ 60 kDa) analysis. The technique is inherently very
sensitive, requiring only sample amounts in the low picomole range and exhibits a
high tolerance towards contaminants (Allmaier et al., 1995). MALDI ion source
utilises energy from laser light that is converted into kinetic energy of the irradiated
molecules or ions. The light gets directed towards a metal target plate of which the
analyte has been crystallized in the presence of matrix molecules. This laser light is
derived from a N2 laser generating UV light with 337nm wavelength. The most
commonly used matrix molecules are -cyano-4-hydroxycinnamic acid for peptides
less than 5000 Da and 3.5-dimethoxy-4-cinnamic acid, or sinapinic acid for proteins
(Lin et al., 2003). MALDI produces predominantly singly charged ions and is less
sensitive to salts in the buffer than ESI, although salt and matrix adducts of analyte
ions can form.
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Electrospray ionization (ESI) is a soft method, allowing the formation of gas phase
ions through a gentle process that makes possible the sensitive analysis of non-
volatile and thermolabile compounds (Manisali et al., 2006).  ESI uses electrical
energy to assist the transfer of ions from the solution into the gaseous phase. The
transfer of ionic species from solution into the gaseous phase by ESI involves three
steps: (1) dispersal of a fine spray of charged droplets, followed by (2) solvent
evaporation and (3) ion ejection from the highly charged droplets (Ho et al., 2003).
The emitted ions are sampled by a sampling skimmer cone and then accelerated into
the mass analyzer for subsequent analysis of molecular mass and measurements of
ion intensity.
1.5.2.3.3 Analyzers
Mass analyzers separates  the ions by their mass  to charge (m/z) ratios utilizing
electric and/ or magnetic fields to manipulate ions in a mass dependent manner. The
mass analyzers that use electric field include time of flight (TOF), quadrupole (Q),
and Ion trap (IT), while magnetic sector and ion cyclotron use magnetic field. TOF
mass analyzer accelerates a packet of ions with a set of electric potentials and
differentiates them by time they take to traverse a flight tube. An m/z value can be
calculated from the time  required to move from ion source  to the  detector.
Quadrupole mass analyzer uses radiofrequency (RF) voltage applied to 4 metal rods
with RF voltage of alternate polarity placed on opposite rods. The ratio of RF to DC
selectively  stabilizes the trajectory of ions of particular m/z value as they pass
through the analyzer.
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1.5.3 Verification of protein identifications
Proteomics studies and the information obtained from such studies can be a great step
towards understanding conditions that get to be studied using proteomics. In order to
have a stronger point from proteomics studies especially in the expression proteomics
alternative approaches that verify the proteomics findings need to be used. The most
utilized ways of verifying proteomics findings are Western blotting and enzyme-
linked immunosorbent assay (ELISA). These two methods have been utilized in
biomedical sciences for a long time because of their sensitivity. Because proteomics
is involving a lot of approaches including the identification of highly expressed or
least expressed proteins these two methods then get to be used to see if they also give
the same result. This enables an enhanced confidence to the research or the study in
question.
1.5.3.1 Western blot
Western blotting is a technique that is used to detect a protein from a sample with
very high sensitivity. The commonly used approach involves the use of SDS PAGE
to separate the proteins by their molecular weight, followed by transferring  of
the proteins to a  nitrocellulose or  polyvinylidine fluoride  (PVDF)  membrane.
The primary antibody that recognises specifically the protein of interest on the
membrane is added after blocking the membrane with BSA or fat free milk to avoid
non-specific binding of the primary antibody to the membrane (Bergendahl et al.,
2003). The secondary antibody (for example, goat anti-mouse IgG) recognizes
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the primary antibody according to its origin (for example, mouse), since it
generally binds to all immunoglobulins from the particular organism that the primary
antibody was isolated from.  The second antibody is typically conjugated with an
enzyme catalyzing a reaction that turns a colourless compound into a detectable dye
and can be used universally with compatible primary antibodies. Older procedures
used radioactively labelled secondary antibodies for sensitivity purposes, but recent
developments make use of luminescent systems that reach similar performance
without the disadvantages of working with radioactivity (MacPhee, 2010).
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Figure 1.4: A schematic of ECL reaction and detection adapted from (MacPhee, 2010)
1.5.4 Blood, plasma and serum use for proteomics
1.5.4.1 Sample collection, handling and storage
Serum has been used extensively as a source of clues to various diseases and
conditions. Serum is a potentially the most valuable specimen for biomarker
elucidation because it constantly perfuse the tissues, it might be expected that the
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onset or presence of disease may be determined by measuring the altered presence or
abundance of the constituent molecular species in serum (Tirumalai et al., 2003a).
The standards in collection, handling and storage have been raised by too many
studies. The manual by Gorg, et. al., (2000) is having a lot of procedures in dealing
with serum for proteomics studies (Gorg et al., 2000). Inappropriate handling of
blood, serum or plasma collected for the determination of hormone concentration
may lead to inaccurate endocrine data and diagnosis (Hegstad-Davies, 2006).
Studies on the effects of blood collection on many other types of laboratory suggest
that optimization and standardization of collection tubes is an important element in
reliable and standardization of collection tubes is an important element in reliable
analysis of serum or plasma proteins (Luque-Garcia and Neubert, 2007). Various
tubes have been studied by Drake et. al. (2004) and they found seven out of eleven
tubes tested to add polymeric components to give multiple signals in the range of
1000-3000 m/z using saline instead of serum or plasma to eliminate confusion of
thinking the peptides are from plasma or serum (Drake et al., 2004). The use of
anticoagulants has also been mentioned to have the changes to mass spectrometry
protein profiles. The best temperature to store blood before separation is 4C
(Skogstrand et al., 2008). Clotting time plays a role in the outcome of the serum
study. Significant differences in MS protein/peptide peak intensities depending on
clotting time. This is associated with the formation/accumulation of new peptides
during and after the clotting process (Villanueva et al., 2005). Many studies showed
that the changes are not seen with the storage of serum for 24 hours at 4C but
changes start to show beyond that storage time (Marshall et al., 2003). Furthermore
 
 
 
 
61
the storage was also found to be efficient at -20 to -80C with some controversy
regarding the freeze thaw cycles which can be avoided by aliquoting (Luque-Garcia
and Neubert, 2007).
1.5.4.2 Depletion of highly abundant proteins
There is a huge challenge encountered when working with serum protein. This is
attributed to by the availability of highly abundant proteins that contribute about 90%
of proteins found in serum causing the difficulty in analysis of low abundant proteins.
Strategies to accomplish success in studies that involve serum have been
previously published. Amongst the listed approaches to depletion of high abundant
proteins is the centrifugal ultrafiltraction, which utilizes the semi-permeable
membrane to separate the proteins based on the molecular weight cut offs (MWCO)
by centrifugal forcing of the liquid against the membrane. Special solvent conditions
are required to disrupt protein-protein/ peptide interactions so that LMW components
that may be bound to albumin or other large species are released and are free to pass
through the membrane (Tirumalai et al., 2003b).
One  or more analytes can also be removed using  solid phase extraction using
columns or disk plates. Solid phase extraction columns are probably the most widely
used for depletion of highly abundant proteins in plasma/serum samples as a first step
in biomarker-related proteomics studies (Luque-Garcia and Neubert, 2007). The
depletion columns have various types; they can be based on ion-exchange, metal-
chelating, affinity ligands, bacterial proteins, antibodies, or combinations of these.
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Solid phase extraction disks utilize the same principle as the columns. The main
advantage associated with solid phase extraction disk plates is the increased ability
for automation. The disk plates are generally used in a 96-well plate format allowing
simultaneous processing of high number of samples by using robots (Koomen et al.,
2005). The other approach to depletion of high abundant proteins is organic solvent
extraction. The precipitation with organic solvent in the presence of ion-paring agents
dissociates peptides and smaller proteins from large abundant proteins, thereby
facilitating their extraction.
1.5.4.3 TCA/Acetone precipitation of serum/plasma samples
Human plasma proteins originate from a variety of tissue and blood cells as a result
of secretion or leakages. A plasma sample is obtained if the blood is withdrawn in the
presence of an anticoagulant (EDTA, sodium citrate, or heparin) and centrifuged to
remove blood cells (Hu et al., 2006). In the absence of anticoagulant, a serum sample
is obtained after the blood clots and cellular elements are centrifuged and removed.
Lipids are widely present in biological fluids such as plasma complexed with proteins
and this interaction reduces protein stability and might affect pI and MW (Ahmed,
2009). This could be the contributor to serum protein composition to be largely
different f r o m tha t o f p l a s m a . Precipitation in acetone or the combination
of TCA/acetone remove lipids‟ elimination is more effective when proteins are
in association with proteins in membranes (Ahmed, 2009).
Plasma and serum proteome analysis has been hampered by predominance of several
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highly abundant proteins including albumins, immunoglobulins, alpha-1-antitrypsin,
fibrinogen and haptoglobulin and their isoforms and fragments (Hu et al., 2006).
Protein precipitation with TCA/acetone or NaCl/ethanol is a useful approach for
depletion of albumins (Huang et al., 2005, Chen et al., 2005). Removal of abundant
has brought concern regarding whether less abundant serum proteins are removed
along with albumin, hemoglobulins and other commonly depleted proteins, however
the use of 5% acetonitrile in serum provide better enrichment of LMW proteins
(Huang et al., 2005). In this study after depletion of high abundant proteins both
portions that is albumin containing and albumin depleted portion were  used to
account for the loss of loss protein with the albumin. Because of efficiency and the
cost effectiveness the TCA/acetone use for depletion shows to be a useful approach
over columns because of the cost involved with the use of columns.
1.5.5 Application of bioinformatics in obesity research
Bioinformatics is conceptualising biology in terms of molecules (in sense of Physical
Chemistry) and applying “informatics techniques” (derived from discipline such as
applied maths, computer science and statistics) to understand and organise the
information associated with these molecules, on a larger scale (Luscombe and
Gerstein, 2001). The term bioinformatics was coined by Hwa Lim in the late 1980s,
and popularized in 1990s through its association with human genome project
(Goodman, 2002). Bioinformatics is able to combine the wet lab and the readily
available information to create new hypothesis towards the expansion of knowledge
in biomedical research. Through bioinformatics it is now possible for an individual
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skilled in bioinformatics to sort through a genome sequence, select for a gene(s),
determine whether the gene has a known function, design PCR cloning primers and
predict cellular location, molecular weight, solubility, pI, etc. of the protein, all in
silico, i.e. in the computer, before performing any laboratory experiments
(Chakravarti et al., 2000).
The  information generated through research is growing year in year out. It is
necessary to have the findings to be organized and placed in a central location for
efficient progression and generation of answers through research. The integration of
biology and chemistry has been overlooked but currently there is an increase in
collaborations in disciplines. Overall, the key challenge facing bioinformatics and
indeed modern biology is to harness the mass of accumulating data and use it to
create new understandings and new knowledge (Kahn, 2002). The long-term value of
bioinformatics lies not in the tools developed and used, but in the conversion of data
into the practical knowledge required for the delivery of better therapeutics (Persidis,
1999). Through bioinformatics the networks that are created by proteins in different
locations in the body are accumulating to increase the understanding of obesity.
1.5.5.1 Bioinformatics improvements at gene and protein level
Investigation of each gene separately for its likely involvement in the disease process
had to be done manually with the aid of available public database such as Online
Mandelian Inheritance in Man (OMIM), Entrez and genome browsers, but now there
are some promising bioimformatics tools. Six of these new tools are freely available
online and those are Prioritizer, Geneseeker, PROSPECTR and SUSPECTS (P and
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S), Disease Gene Prediction (DGP), Genes 2 Diseases (G2D) and Endeavour (Elbers
et al., 2007) (Elbers et.al., 2006). The information utilized by these tools is extracted
from public online database, such as sequence data, medical literature, gene ontology
and function annotation (GO) and information on biology, function and gene
expression. These tools have been used to identify the common genes in obesity and
T2D.
Bioinformatics is playing a crucial role in speeding up the protein research. Databases
are available for 2D PAGE, mass spectra analysis e.g. peptide mass fingerprint,
protein structure, protein interaction and protein role in metabolic pathways, etc.
Mass spectrometry approaches are being   used in protein identification and
determining the nature of post-translational modifications (Sickmann et al., 2003).
Mass spectrometry and other methods make it possible to quickly identify large
number of proteins, to map their interactions, to determine their location within the
cell and to analyse their biological activities (Apweiler et al., 2004). The databases
that are being used differ in that some are sequence repositories that add little or no
additional information to the sequence records they contain and generally make no
effort to provide a non-redundant collection of sequences to users. Examples of
sequence repositories are GenPept and NCBI‟s Entrez Proteins. Universal curated
databases have additional information that is validated by expert biologists to enrich
the sequence data. Such databases include PIR-PSD, Trembl and Swiss-Prot. Lately
Swiss-Prot, TrEMBL and PIR-PSD have been merged to form the UniProt
knowledgebase. This provides a cornerstone for scientists active in modern biological
research (Apweiler et al., 2004).
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Another purpose of bioinformatics is to enable scientists in various researches to be
able to draw biological conclusions. In recent years, most new generation of
algorithms incorporate information from biological pathways into microarray data
analysis (Goeman et al., 2004, Subramanian et al., 2005). Three popular pathways are
referenced by such algorithms, those are KEGG, Ingenuity and Wikipathways (Soh et
al., 2010). Wikipathways is maintained by a community of professional users via the
free and open wiki platform; KEGG is curated independently by a single lab from
published literature while ingenuity is a commercial product (Soh et al., 2010). The
overall bioinformatics part of this study has been shaped by the above information in
that the databases used are curated databases. For pathway analysis KEGG has been a
database of choice since Ingenuity is a commercial product and was not available for
use.
1.6 Problem statement
Obesity is a disease that is due to the accumulation of body energy stores due to
increased adiposity that results mostly from high energy intake with reduced
dissipation to create an imbalance in energy. The use of body mass index (BMI) and
waist to hip ratio (WHR) has been successful in identifying individuals with obesity
but these methods works to identify the individual at a late or compromised stage
when reversing the condition is quite a challenge especially for the too ambitious
individuals that require results immediately. It is known that adiposity is as a result of
increase in fat storage which happens due to adipocyte differentiation or hypertrophy,
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adipogenesis, and accumulation of free fatty acids in the blood. Blood, as a carrier
of many components of the body and passing through the organs of the body, can be a
useful material to use for tracking the changes that are due to adiposity, which is the
contributor to obesity eventually. We hypothesized that using proteomics to study less
invasively the serum proteins response to high fat diet feeding can reveal the trend that
is taken by proteins in relation to the diets fed based on caloric content. This can lead
to possibility of potential biomarkers being identified towards early detection of
obesity and introduction of means to prevent the perpetuation of obesity.
1.6.1 Aims
 The aim of this study was to compare the changes in serum protein profiles of
rats fed different diets
 To identify the proteins that are differentially expressed in high calorie diet
fed groups compared to the control diet using peptide mass fingerprinting
 To validate the expression using Western blot analysis
 To determine whether the trend that the expression follows is dependent on
diet or time
 To use bioinformatics to gather information on the proteins that were
differentially expressed
1.6.2 Objectives
 To create a diet induced obese male Wistar rat model using a known lard diet
and two other high fat diets that are new to our knowledge
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 To use diets with different calorie content in terms of the energy source but
with equivalent calorie content per gram of diet
 To monitor the intake of food over the duration of the study to make sure that
there are no satiety differences
 To compare the proteome for the groups fed high fats diet compared to the
control diet
 To identify the changes in relation to time by collecting blood at different
time points
 To identify the proteins which are potential markers of response to high
calorie intake
 To gather the information about the proteins found to be potential
biomarkers regarding their role in metabolic pathways to complete the
picture of the findings
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Chapter 2: Materials and Methods
2.1 Materials and suppliers
Accucheck Precision Glucometer (GlaxoSmithKline)
Acetonitrile (Sigma Aldrich)
Acrylamide/ Bis acrylamide (Sigma Aldrich)
Ammonium persulfate (Promega)
Antibodies (Santa Cruz Biotechnology)
Biolyte Ampholytes (Bio Rad)
Bovine Serum Albumin (Sigma Aldrich)
Bradford reagent (Sigma Aldrich)
Bromophenol blue                                                   (Merck)
Carbon dioxide (Afrox)
CHAPS (Sigma Aldrich)
Chemiluminescence X ray film (GE Health Care)
Chow (Epol)
Coomassie brilliant blue R 250 (Sigma Aldrich)
Dithiothreitol (Sigma Aldrich)
ECL detection reagent (Amersham)
Eppendorff microcentrifuge 5417R (Sigma-Aldrich)
Fat free milk (Nestle)
Filter papers (Bio Rad)
Gel casting apparatus (Bio Rad)
Glacial acetic acid (Merck)
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Glycerol (Merck)
Glycine (Sigma Aldrich)
Hydrochloric acid (Merck)
Immobiline dry strip reswelling tray (GE Health)
IPG strips (7cm, pH 4-7) (Bio Rad)
Lauryl sulphate (Sigma Aldrich)
Lumiglo (KPL)
Mini-Protean III multi casting chamber (Bio Rad)
Polyvinlidene Fluoride membrane (PALL Life Sciences)
Sodium chloride (Merck)
Thiourea (Sigma Aldrich)
Trichloro-acetic acid (TCA) (Sigma Aldrich)
Tris (Hydroxymethly) Methan                                 (Merck)
Trypsin (Promega)
Tween 20 (BioRad)
Urea (Sigma Aldrich)
Vortex (Whitehead Scientific)
Voyager-DE PRO MALDI MS (Applied Biosystems)
X-ray film processor (Agfa)
Zip Tips (Millipore)
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2.2 Search engines and software used
MASCOT (Matrix Science: http://www.matrixscience.com)
Image J (National Institute of Health)
PD Quest (Bio Rad)
Quantity One (Bio Rad)
KEGG Kyoto Encyclopedia of Genes and Genomes
2.3 Solutions
1.5 M Tris-HCl, pH 8.8 18.17 g Tris-base, set pH to 8.8 with
HCl and make up to 100 ml with ddH2O
10X TBS 25 mM Tris, 150 mM NaCl, 2 mM KCl,
10% APS 1 g ammonium per sulphate, 10
ml ddH2O
10% TCA/acetone 10 ml Trichloroacetic acid, 90ml acetone
10X running buffer 250 mM Tris, 1.92 M Glycine, 1% SDS
1X Running buffer 25 mM Tris, 192 mM Glycine, 1% SDS
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5% blocking solution 5 g fat free milk in 100 ml TBST
add distilled H2O to a litre
Agarose sealing mixture 0.5% (w/v) agarose, 0.002% (w/v)
bromophenol blue in 1X running buffer
Coomassie de-staining solution 7% Ethanol, 2% acetic acid, fill up to 1L
with ddH2O
Coomassie staining solution 10% Ethanol, 7% Acetic acid, 0.05%
Coomassie Blue R-250
Equilibration buffer 1 6 M Urea, 135 mM DTT, 30% Glycerol,
45 mM Tris base, 1.6% SDS, 0.002%
bromophenol blue
Equilibration buffer 2 6 M Urea, 130 mM IAA, 30% Glycerol,
45 mM Tris base, 1.6% SDS, 0.002%
bromophenol blue
Lysis buffer 9 M Urea, 2 M thiourea, 4% CHAPS
in ddH2O
Ponceau staining solution 0.1% Ponceau S (w/v) in 5% Acetic acid
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Sample buffer 4.2 ml [0.5 M Tris-HCl pH, 6.8 (1 ml);
800 l Glycerol; 1.6 ml 10% SDS (w/v);
400 l 2-mercaptoethanol; 400 l
0.05% (w/v) bromophenol blue]
Stripping buffer 20 ml SDS 10%; 12.5 ml of 0.25 M
Tris, pH 6.8; 67.5 ml ultra pure water;
0.8 ml β-mercaptoethanol
TBST 100 ml of 10X TBS, make up to 800 ml
with ddH2O, set pH to 7.6 with HCL, fill
up to 1 L with ddH2O, add 0.05%
Tween 20
Transfer buffer 25 mM Tris, 192 mM Glycine, 10%
(v/v) Methanol
Tris-HCl, pH 6.8 6.06 g Tris-base, set pH to 6.8 with
HCl and make up to 100 ml with
ddH2O
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2.4 Diets and feeding regimens
A diet-induced obesity study deserves careful planning of the high fat diets to avoid
confounding factors like using cereal based diets as control diet like chow for purified diets
(Gadja, 2008). In this study we used chow to formulate the diets. The lard diet was used before
in the Medical Research Council’s Research laboratory to study obesity (Sibuyi, 2009). The
butterfat was used as a different source of energy and there is no work that has been published
before that uses butterfat. Protein content was increased by the addition of fat free powdered
milk to the lard fat free diet. The maintenance diet was also complemented with protein by
adding fat free milk to the chow diet.
2.4.1 Preparation of the diets
Diets used in the present study were prepared in-house at the Medical Research
Council’s Diabetes Research laboratory. The ratios given in tables above are given
for the preparation of a 100 grams diet. The dry material was weighed first for each
diet. The mixing   was performed after each addition. The fat and sunflower
oil were mixed before adding to the mix. A litre of water was added for every four
kilograms of diet. The diet was put on trays and flattened. The pizza cutter was used to
cut it into small blocks for feeding. The diet was placed at 4C walk in fridge for the
solidification and storage. The diet was ready for feeding four hours after
preparation. Obesity was induced by feeding the rats ad libitum diets are shown on
tables.
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Table 2.1 (a): Maintenance diet (C)
Chow (g) Fat free powd. milk (g) Total (g)
Ratio 50 50 100
Protein 0.09 0.1605 0.2505
CHO 0.3975 0.2605 0.667
Fat 0.0125 0.0005 0.013
g/g of diet 0.5 0.5 1.0
kJ/g diet 5.5 7.225 12.725
Kcal/g diet 1.315 1.727 3.041
Table 2.1 (b): Lard high fat diet (L)
Chow (g) Lard (g) Sumfl. Oil (g) Sugar (g) Vit. & min. (g) Total (g)
Ratio 54.8 32 1.6 6.4 5.2 100
Protein 0.09864 0 0 0 0 0.09864
CHO 0.43566 0 0 0.064 0 0.49966
Fat 0.0137 0.32 0.016 0 0 0.3497
g/g of diet 0.548 0.32 0.016 0.064 0.052 1
kJ/g diet 6.028 4.84 0.6112 1.08672 0 18.4792
Kcal/g diet 1.441 2.83 0.116 0.26 0 4.41663
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Table 2.1 (c): Lard Fat Free Powdered Milk Diet (LF)
Chow (g) Lard (g) Fat free powd. milk (g) Sunfl. Oil (g) Total (g)
Ratio 50 17.5 32 0.5 100
Protein 0.09 0 0.10272 0 0.19272
CHO 0.3975 0 0.17248 0 0.56998
Fat 0.0125 0.175 0.00032 0.005 0.19282
g/g of diet 0.5 0.175 0.032 0.005 1
kJ/g diet 5.5 6.475 4.624 0.191 16.79
Kcal/g diet 1.315 1.548 1.105 0.064 4.013
Table 2.1 (d): Butterfat diet (BF)
Chow (g) Full cream powd. milk (g) Total (g)
Ratio 50 50 100
Protein 0.09 0.1185 0.2085
CHO 0.3975 0.197 0.5945
Fat 0.0125 0.14 0.1525
g/g of diet 0.5 0.5 1
kJ/g diet 5.5 10.6 16.1
Kcal/g diet 1.315 2.533 3.848
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2.4.2 Dietary fatty acid analysis by GC MS
Dietary fatty acids were quantified following the method similar to the one used by
van Jaarsveld et. al. (2000), using heptadecanoic acid as an internal standard (Sigma
Aldrich). Freeze dried food sample (2 g) was homogenized in 50 ml of
chloroform/methanol (2:1) v/v containing 0.01% butylated hydroxytoluene (HBT)
with a polytron. The homogenate was filtered with sintered glass funnels and the
filtrate made up to 50 ml with chloroform/methanol (2:1) v/v. To 1 ml of the
extract, 1ml of a 30 ug/ml heptane solution of heptadecanoic acid internal standard
was added and solvents evaporated to dryness at 40C under stream of nitrogen gas.
To the dry residue, 2 ml of a 6% ethanolic-KOH solution was added, followed by
heating at 70C in an aluminium block for 2 hrs. After cooling, 1 ml of water and 2
ml of n-hexane were added and the samples were thoroughly mixed on a Vortex
mixer. Of the top hexane layer, 1 ml aliquots were evaporated to dryness and re-
dissolved in CS2. Aliquots were then injected into a Varian Model 3700 GLC
equipped with a flame ionization detector and a 1.2 m glass column (2 mm internal
diameter) packed with 3% SP-2401 on 100/120 mesh Supelcoport (Supelco Inc.,
Bellefonte, PA, USA). Gas flow rates were: hydrogen, 20 ml/min; air, 200
ml/min; and nitrogen carrier gas, 25 ml/min. Temperatures were: injector, 280C;
column, 255C; and detector, 290C.
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2.5 Induction of obesity using different high fat diets in a Wistar rat model
Twenty eight male Wistar rats were obtained from the Medical Research Council’s
Animal facility in Tygerberg (South Africa) at weaning. They were maintained on
chow for four weeks. After four weeks the rats were body weight-matched and
divided into four groups. They were single caged in wire meshed cages to allow
food monitoring. The weights that were recorded during the grouping were used as
baseline weights and the animals were assigned to different dietary groups.
One group was continued on maintenance diet while three groups were switched to
different high caloric diets. All animal protocols used in this study were approved
by the University of Stellenbosch’s Animal Ethics Committee.
2.5.1 Food intake and body weight measurements
To monitor the intake, food was weighed before giving it to the rats. Food spillage
and food left was subtracted from the food given, to get the intake per rat. The
average was used to determine intake per week. Body weights for the rats in different
groups were recorded weekly. The body weight gain for each group was plotted in the
graph as an average of the group’s weight per week for the duration of the study that
took eight weeks.
2.5.2 Blood glucose measurement and serum preparation
The animals were anaesthetized using 98% oxygen and 2% fluothane. The
glucometer Precision ACCU check was calibrated using the calibration strip. The
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strip was then substituted with a glucose strip for glucose measurement. The tip of the
tail was cut using the scalpel. After cutting the tip of the tail a drop was placed on the
glucose strip, blood glucose was measured following the manufacturer’s instructions
and the reading was recorded. A red light was used to warm the tail to enhance the
blood flow to the tail. Blood was collected drop by drop into a 1.5 ml eppendorf
tubes to a volume of approximately 100 l. The tubes were kept on ice during
collection until the blood was collected from all the groups. The tubes were removed
from ice and centrifuged at 800 x g in a 4C pre-cooled centrifuge for 15 minutes.
The serum was transferred to new tubes in aliquots of 50 µl and stored at -80C until
use. This was performed at baseline, after 4 days and after 4 weeks during the obesity
induction period.
2.5.3 Termination of animals and tissue collection
After eight weeks the animals were terminated for blood and tissue collection. The
rats were anaesthetized using carbon dioxide and terminated by decapitation. A drop
of blood was used to measure glucose as in 2.4.2. The blood was collected into a
10ml tube and the tube was placed on ice to clot. Serum was prepared as explained in
2.4.2. This was performed for each rat involved in the experiment. The rats were
dissected using a sterile dissection kit. A pair of scissors was used to cut out fat pads
which include inguinal, retroperitoneal, perirenal, epidydimal and mesenteric fat pads.
Other tissues that were collected include brain, liver, pancreas, spleen, kidneys, heart
and adrenals. The tissues were removed from an animal, weighed and snap frozen in
liquid nitrogen. Collected tissues were stored in foil at -80C.
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2.6 Protein expression analysis in serum using proteomics
2.6.1 Depletion of highly abundant proteins using TCA/acetone precipitation
Frozen samples were thawed and 50 µl of distilled water was added to an equal
amount of the sample. To make a mixture homogenous a vortex was used. Four
volumes of ice-cold 10% TCA-acetone (v/v) were added, and mixed by vortexing.
The sample was incubated at -20C for 90 minutes. Centrifugation at 16000 x g at
4C for 15 minutes was performed and supernatant was carefully removed to a new
tube. The pellet was washed once with 500 µl of ice-cold acetone. The pellet was
incubated on ice for 15 minutes. The tube was centrifuged at 16000 x g at 4C for 15
minutes; supernatant was added to the tube with the first supernatant and remnants of
acetone were blotted using the paper towel. The tube with the supernatants was
incubated at -20C for 1hour after adding 500 µl of ice-cold acetone to make ~1500
µl. The tube was then centrifuged at 16000 x g at 4C for 15 minutes and the
supernatant was discarded and the paper towel was used to blot the remaining liquid.
Pellets were resuspended in 100 µl lysis buffer (LB) (9M urea, 2M thiourea, 4%
CHAPS). The first pellet was albumin depleted and the second pellet contained
albumin.
2.6.2 Analysis of protein concentration using Bradford assay
The protein concentration was determined for each pellet as obtained in 2.5.1 using
the Bradford assay. One µl of the sample was diluted with 49 µl of the solubilisation
buffer. The standards were prepared using known amounts of bovine serum albumin
(BSA). To 25 µl of diluted sample or BSA standard 1 ml of Bradford reagent was
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added. The mixture of Bradford reagent and sample or BSA standard was incubated
at 37C for 30 minutes. The samples or BSA standards were then added to a
microplate (125 µl/well) in triplicates. The plate was read on a spectrophotometer at
wavelength 630 nm. The BSA absorbance values obtained were used to draw a
standard curve. The concentrations of the samples were determined from the standard
curve.
2.6.3 Analysis of TCA/acetone treated samples using SDS-PAGE
Quantified samples were mixed with an equal volume of 2X sample buffer (1:1). The
samples were then boiled for 5 minutes. Fifty micrograms were loaded per well in a
12% SDS- PAGE with 5 µl Fermentas protein marker loaded in one well. The
samples were electrophoresed at 120V (constant voltage) until the dye reached the
bottom of the gel. The gel was removed from the glass plates, stacking gel was
removed and the resolving gel was stained using Coomassie stain. Gel images
were taken using the Bio-Rad gel doc system.
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A B
Figure 2.1: Fermentas markers that were used in gel electrophoresis (https://www.fermentas.com)
PageRuler  Unstained  Protein  Ladder  (A)  and  PageRuler  Plus  Prestained  Protein Ladder (B)
2.6.4 Isoelectric focusing of proteins from TCA/acetone treated samples
Proteins samples as prepared in 2.5.1 were mixed with ampholytes, 50mM DTT,
Lysis buffer to 200l total volume recommended for the 7cm strips of 200g total
protein. The mixture was added in the re-swelling tray one sample each lane. The
IPG strips were opened and placed gel towards the loaded sample on a reswelling
tray. The tray was left for passive re- swelling overnight (at least up to 16 hours). The
re-swollen strips were then placed on the isoelectric focusing machine and wet filter
papers were put on edges prior to placing the electrodes.  The machine was turned on
and ran using the following protocol: first step at 7000V for 15 minutes, second step
8000V for 30 minutes and strips were run at 6475 Vhr running 12 strips.
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2.6.5 Separation of protein on a second dimension following IEF
The strips were removed from the IEF machine and rinsed with distilled water.
Excess water was blotted using a paper towel. The strips were then placed on the re-
swelling tray gel-side up. The strips were equilibrated using equilibration buffers 1
and 2 respectively for 15 minutes each with shaking. During equilibration the protein
ladder was added to ~4 mm2 filter paper and left to dry. The 12% SDS PAGE was
prepared without stacking gel. The equilibrated strips were rinsed with 1x running
buffer and loaded on top of the SDS PAGE gel leaving a space for a filter paper space
on the left side. The filter paper was loaded using a pair of forceps. To seal the strips
and filter paper, cool 1% agarose gel with bromophenol blue was used. After
polymerization of sealing agarose the SDS PAGE was run at 120V constant voltage
until the dye reached the bottom of the gel.
2.6.6 Staining and imaging of SDS PAGE and 2D SDS PAGE
Gels were stained with Coomassie 1 overnight, Coomassie 2 for 30 minutes, and
Coomassie 3 for 30 minutes. The gels were then destained using a destaining solution
until a clear background was obtained and protein spots or bands were clearly visible.
The gels were scanned using Bio Rad Pharox FX Imager and images were saved
using Quantity One software. Saved images were cropped leaving the protein ladder
off and processed to better visibility. The cropped images were loaded to PD Quest
software for analysis.
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2.6.7 PD Quest analysis of 2D SDS PAGEs for differentially expressed proteins
The loaded images 2.5.6 were analyzed using PD Quest software. The spots
comparisons were performed after choosing the control group and experimental
groups. The spots were either added or subtracted from gels to get the similar number
of spots to compare across the groups. The spots were manually compared within and
between groups to ensure the consistency in spots to be compared. The parameters
that were to be used for analysis were chosen. The spots that were two fold high or
less in intensity  in experimental groups compared to control were considered
enhanced or deregulated respectively. Those spots were considered for identification
with MALDI MS.
2.6.8 Protein spots excision and in-gel digestion for MALDI TOF MS analysis
Spots that were considered to be differentially expressed from the experimental
groups were excised using a pipette tip and placed in a sterile eppendorff tube. Water
was added to a gel plug for rehydration and rinsing. Water was removed and 35 µl of
acetonitrile was added to a gel plug. The gel plug was incubated with acetonitrile at
room temperature (RT) for ten minutes to shrink and dehydrate. Acetonitrile was
carefully removed using a sterile pipette and a gel plug was dried for ten minutes in a
speed-vac. A re-swelling buffer [150 µl of 10 mM DTT in 100 mM NH4HCO3] was
added and the tubes were incubated for 1 hr at 56C. After 1 hr incubation the tube
was cooled to RT and DTT solution was replaced with 150 µl (55 µl iodoacetamide in
100 mM NH4HCO3]. Incubation at RT for 45 minutes with occasional mixing by
vortex was performed. The iodoacetamide solution was replaced with 150 µl of
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acetonitrile and the tube was incubated at RT for 10 minutes. The washing steps were
repeated as above. Acetonitrile was removed and a gel plug was dried by speed-vac
for 10 minutes. The tube was placed in an ice cold water bath and a gel plug was
swollen in 35 µl of digestion buffer [12.5 ng/µl trypsin (Promega sequence-grade
modified porcine trypsin cat. 511A) in 50 mM NH4HCO3]. The tube was left in ice
water bath for 45 minutes after which the digestion buffer was removed. Ten
microliters of 50 mM NH4HCO3 without trypsin was added and incubated at 37C
overnight. The gel plug was spun down for 1 minute at 14000 rpm. The supernatant
was collected into a separate PCR tube. Twenty microliters of 20 mM NH4HCO3
enough to cover the gel plug was added. The tube was incubated for 10 minutes at
RT. The supernatant was transferred to the PCR tube. Twenty five microliters of 5%
formic acid, 50% acetonitrile were added to gel pieces and tubes were spun at 14000
rpm for 1 min, followed by transfer of formic/acetonitrile solution to the same PCR
tube as above. The formic acid extraction was performed twice. The PCR tube was
spun on the speed-vac to reduce the sample volume to approximately 10 µl. The
digests were desalted with C18 Zip Tip and eluted with 70% acetonitrile and 0.1%
Trifluoroacetic acid (TFA). The eluted peptides samples were mixed with saturated
matrix of HCN spotted on a MALDI plate and analyzed using MALDI TOF TOF
(Voyager-DE PRO). Generated mass sprectra from MS were loaded to MASCOT for
identification. The high scoring identification from MASCOT was considered.
2.7 Verification of differentially expressed proteins by Western blot analysis
Proteins were  obtained from the serum as explained in section 2.5.1 and an
equal amount of sample and the sample buffer were mixed in a tube. The
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mixture was boiled for 5 minutes using a heating block, removed and spun down. The
sample was loaded on a 12% SDS PAGE. The gels were run until the dye front
reached the bottom of the gel. The gels were removed and plated into container
containing the transfer buffer. The PVDF membrane was cut according  to the
size of the gels, put in methanol for 30 seconds, rinsed in distilled water and set in
the transfer buffer for 5 minutes with shaking. Filter paper and the foam were also
prepared by immersing in the transfer buffer for about 15 minutes. The foam, filter
paper, gel, membrane, filter paper, foam setup was done avoiding bubbles between
membrane and the gel. The cassette was assembled and loaded in to the electrode and
set in the tank. The transfer was performed at 150V constant voltage for 60 minutes.
At the end of the run the membranes were removed and rinsed with TBST. The
rinsed membranes were incubated in blocking solution [5% fat free powdered milk in
TBST] for 1 hour with shaking. The blocking solution was removed and the
membrane was washed 3 times with 1X TBST for 10 minutes each. The membrane
was probed using a primary antibody 1:1000 overnight at 4C with shaking. The
membrane was washed with TBST as above and probed using the secondary antibody
1:4000 in blocking solution for 2 hours. The membrane was washed as above. The
proteins were detected using the Lumiglo s ys t e m (KPL). Equal amounts of
solution A and B were mixed in the dark room with the safe light on. The mixture
was applied in the membrane protein side up to cover the membrane. After a minute
the mixture was removed and excess was blotted using a paper towel. The membrane
was wrapped in a transparent plastic placed in the cassette and the hyper-film was
placed on top of the wrapped membrane. The cassette was closed and the exposure
was timed at  30 sec,  3 minutes, 5 and  10 minutes. The picture of a film was
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shot using the Gel doc system and the pictures were saved for analysis using the
Image J software (Schneider et al., 2012). The densitometric volumes were used to
compare the expressions.
2.8 Bioinformatics analysis and acquisition of information from databases
2.8.1 MASCOT identification of proteins
The proteins identified to be differentially expressed were f u r t h e r identified
using mass spectrometry whereby the MASCOT database was used to compare the
spectra as generated during mass spectrometry analysis. The identifications were
taken based on the MOWSE scores. Highest MOWSE scores were considered to be
the reliable identifications. Expasy was used to acquire the information that is
readily available for the proteins that were identified to be differentially
expressed. Using the orthology the links of the proteins identified with the pathways
for metabolism were identified. The KEGG pathway analysis was used for this
analysis.
2.8.2 Retrieval of protein information from Expasy
2.8.2.1 Uniprot information retrieval for proteins identified to be differentially
expressed
The information about the proteins that were identified was obtained from the Expasy
proteomics server.  The protein name was used to get the  information from the
Uniprot database.
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2.8.2.2 The PMP database use for available modelled structures of the protein
From the information acquired the accession number was used to get the structure as
modelled in the Protein Model Portal database. The experimental structure of the
protein was chosen when available. If the experimental structure is not available the
modelled structure with highest sequence identity (ID) was used.
2.8.3 Orthology approach for identification of association of identified proteins to
pathways using KEGG
The proteins were searched for their role in metabolic pathways. The information was
not available. To get the association of the proteins with other pathway the orthologs
of the proteins in questions were identified. The k values of the proteins were
obtained and the search was performed on a KEGG pathway database. The highest e
value was considered for protein’s association with pathways. The pathways were
considered for analysis and the literature was used to acquire more information on
proteins.
2.9 Data analysis
The diet effects were tested by means of a linear mixed effects regression model. The
fixed effects tested were diet, time and diet by time interaction. The random effects
for each rat is a linear model on time with an intercept and slope as the parameters.
A procedure “lme” in R Program was used for a linear mixed effects regression
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model. This is the model that we used: Weight = Diet + Diet*log (Time), 1+log
(Time) /Rat……………………(1)
This is a model that takes into considers the change in the body weight cumulatively in
relation to time. Diet is the initial body weight for each dietary group, whereas Diet*
represents the weight in the successive weeks. It takes into consideration the time
effect to weight gained.
Unless stated otherwise, all the other parameters were analyzed using the One way
ANOVA (Graph Pad Prism 5). The values were considered to be statistically
significant when p ≤ 0.05.
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Chapter 3: Induction of obesity using different diets
3.1 Introduction
There is no clear evidence to reveal the specific component of a diet (i.e.
carbohydrate, fat, protein, vitamins, micronutrients) that influences the ways in which
food energy is absorbed or used (Scheen, 2008). However it is an established fact that
many strains of rats become obese when fed palatable diets containing large amounts
of fat and most of the weight increase is carcass fat (Cobertt et. al. 1986). It is
important to mention that the use of a high fat diet to create an obese animal model by
researchers contributed to the gathering of information about obesity both in rats and
mice. The type and amount of fatty acids used to prepare the diets has significant
effects in various metabolic processes. The field of dietary research has looked more
at fat consumption than the effect of glucose metabolism which is also found to
contribute to the control of weight (Lichtenstein and Schwab, 2000). The rise in
obesity and metabolic syndrome has been noticed and attributed to the global
nutrition transition. A noticeable transition from traditional plant-based to more
energy dense diet dominated by processed foods, sugar and high animal fat content
together with sedentary lifestyle has been seen globally (Kimokoti and Millen, 2011).
An increased fatty acid content of the diet alters plasma lipoprotein profiles with an
increase in the variety of fatty acids in terms of their chain lengths and the degree of
saturation (Medei et al., 2010). The current study utilizes gas chromatography to
analyze fatty acid profiles for the four diets that were used during obesity
induction. Other parameters that were analyzed include food intake, body weights,
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blood glucose, adiposity and various tissue weights to get the physiological
changes that are involved with dietary intake. The physiological response is widely
used whereby the difference in tissue size tells the effect of diet. The following results
show the change in weights, blood glucose, adiposity (fat depots) and the difference
in fat contribution to the whole body weight (adiposity index).
3.2 Analysis of fatty acids in different diets using GC MS
The analysis of fatty acids for the diets was performed using the GC MS as detailed
in Section 2.3.2. Results obtained were showed high percentages of saturated fatty
acids for  the three high fat diets compared to the control diet (Figure 3.1).
Significantly high amounts of unsaturated long chain fatty acids [(linoleic acid
(18:2)] content were found in the control diet than the three high fat diets. Significant
in contrast the three high fat diets were high in the saturated long chain fatty acid
[(stearic acid (18:0)] Table 3.1. The amounts of [palmitic acid (16:0)] were also high
for the high fat diets with highest percentage contribution seen in the butterfat.
T h e  b utterfat diet contained two folds or more of medium chain saturated fatty
acids [myristic (14:0)] than the other two high fat diets and the control diet. The
amount of monounsaturated fatty acids [oleic acid (18:1)] was close in percentage
contribution across the diets Table 3.1.
Looking at the tabulated amounts for the diets (Table 2.1 a-d) it shows the
distribution of fat contents between diets. It is noticeable that the control group has
a very low fat content per gram of diet Table 2.1 (a). The dominant fatty acids
 
 
 
 
92
Names of fatty acids Systemic name C LF L BF Type of FAs
% contribution to total fat
-linoleic acid (18:3 n-3) 9,12,15-octadecatrienoic 4 1 1 0 Unsaturated
-linoleic acid (18:3 n-6) 6,9,12-octadecatrienoic 0 0 0 1 Unsaturated
Arachidic acid (20:0) Eicosanoic 1 1 0 1 Saturated
Palmitoleic acid (16:1 n-7) Cis-9-hexadecanoic 1 1 2 2 Unsaturated
Myristic (14:0) Tetradecanoic 1 8 3 3 Saturated
Palmitic acid (16:0) Hexadecanoic 17 23 24 23 Saturated
Stearic acid (18:0) Octadecanoic 7 15 22 22 Saturated
Oleic acid (18:1 n-9) Cis-9-octadecanoic 27 33 39 37 Unsaturated
Linoleic acid (18:2 n-6) 9,12-octadecadienoic 42 9 9 11 Unsaturated
in the maintenance diet were polyunsaturated. More than 70% of the fat is
unsaturated fat in the control diet. Overall the dominant fatty acids in the lard diet
were saturated. There was no significant difference in the calories between the high
caloric diets but the other two diets unlike the lard diet have a bit more calorie
contribution from proteins and carbohydrates.
Table 3.1: GC MS results of fatty acid percentage contribution to the total fat in diets used
The diets which are maintenance diets (C), lard diet (L), lard fat free diet (LF) and butterfat diet (BF)
were analyzed for their fatty acid profile. The fatty acids that are contained in each diet are given in the
table under each diet in percentages. A scientific name of the fatty acid is given in the first column and
the last column states the type of fatty acid
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Figure 3.1: Percentage contribution of fatty acid to the total fats for the four diets used as
analyzed by GC MS
Saturation of fats between diets is different with high percentage of un-saturation for the maintenance
(C) diet. Three high fat diets i.e. lard fat free (LF), lard (L) and butterfat (BF) diets have the similar
percentages of polyenoic fatty acids. The BF diet contained high amounts of saturated fats with least
percentage of saturated fats in the C diet.
 
 
 
 
94
3.3 Induction of obesity by feeding different high fat diets in a Wistar rat model
The rats obtained at weaning  were fed maintenance diet for four weeks for
acclimatization followed by induction of obesity as explained in S ection 2.4.
Feeding high caloric diet to rats resulted in high weight gain for the rats on high
caloric diets compared to the rats on maintenance diet. The effect of feeding high
fat diet was recognised as early as the second week. Significant difference in
weights for the animals that were fed lard high fat diet was recognised as early as
week two whereas the animals on butterfat (BF) and lard fat free milk (LF) diet
showed difference at week three. The differences in weights were seen throughout
the experimental period for L and LF (p<0.001) when compared to the C diet
fed group. The difference in body weight was also significant (p<0.05) for the BF
fed group compared to the C fed group with group on BF being heavier. There
was a response shown for the collection of blood at four weeks which was due to
the starvation before blood collection. The control group showed a drop in body
weight at week five, but it rose again at week six (Figure 3.2 A).
Food intake was monitored throughout the study as detailed in Section 2.4.1. The food
intake by the group on the maintenance diet was high compared to the groups on high
caloric diets (Figure 3.2 B). The cumulative food intake also showed a similar
trend but w i t h the g r o u p  o n  m a i n t e n a n c e diet having highest intake
throughout the duration of the study though the rats started taking equal amount of
food in the first week (Figure 3.3 A). The energy intake was the inverse of the
food intake as seen in (Figure 3.3 B), w h i c h  w a s due to the dietary content
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that was found in different diets. The dietary content for C (1.3% fat, 67% CHO, 25%
protein) contained the least fat amount than L (35% fat, 50% CHO, 10% protein); LF
(19% fat, 57% CHO, 19% protein) and BF (15% fat, 59% CHO, 21% protein). More
energy intake was from the L diet and this can be attributed to the high fat content
with the least energy intake from the E diet but the difference was not significant.
These results shows that the intake between the groups was not  varying much
based on the amount of food and energy intake needed per rat. These results suggest
the differences in body weights to be due to the differences in energy storage
between the groups.
 
 
 
 
96
w
ei
gh
t
(g
)
C
um
ul
at
iv
e
fo
od
in
ta
ke
(g
)
550
500
450
Body weights A
* *
* C
* L
* LF*
* BF
*
400
350
0 2 4 6 8 10
Time (weeks)
1500
Food intake B
1000 * * *
500
0
Figure 3.2: Rats body weights for eight weeks of obesity induction (A) and the amount of total
intake over eight weeks per rat (B).
The figure (A) represents the body weight for the dietary groups which are maintenance diet fed group
(C), lard fed group (L), lard fat free group (LF) and butterfat fed group (BF) for the duration of the
experiment (8 weeks). The cumulative intake which is the average intake per rat throughout the period of
the experiment is shown in B with low intake for the groups on high fat diet (p < 0.05).
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Figure 3.3: Cumulative energy (A) and food intake (B) over the period of eight weeks for all the
dietary groups
The cumulative weekly food intake is shown in (A). Intake for the group on maintenance diet (C)
being the highest followed by the butterfat fed groups. The lard and lard fat free groups show a
similar intake. The cumulative caloric intake (B) shows to be the reverse of the food intake with C
fed group having the lowest energy intake and the L fed being the highest.
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B
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3.4 Measurement of blood glucose and collection of blood for serum preparation
To monitor the chances in glucose levels, blood glucose was measured during the
blood collection time points (Section 2.4.2). Blood glucose levels were not
significantly different throughout the study. The group on BF diet showed high blood
glucose levels at termination compared to the control group. The initial glucose levels
were high but the levels eventually dropped. The other two groups on high caloric
diets were having low blood glucose levels compared to the control group but the
difference was not significant (Figure 3.4). The rise in glucose levels during
the second collection time point could be attributed by blood collected under
anaesthesia. Glucose measurements at termination were also performed after the
carbon dioxide anaesthesia and decapitations. The glucose response can be at worst
being associated with the  pre-diabetes state  but the rats were not diabetic at
termination. At termination the postprandial glucose were 5.96±0.18, 8.52±0.39,
7.28±0.35 mmol/l for L, LF and C respectively. There was a rise in the BF group
with postprandial glucose levels reaching 11.92±2.05 mmol/l.
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Figure 3.4: Glucose measurements from baseline to termination.
Baseline glucose measurements show similar levels for maintenance diet fed group (C), butterfat fed
group (BF), lard fat free fed group (LF) and lard fed group (L). The levels rose for all the dietary groups
during day four especially the C group. The levels were at normal levels when measure after four weeks
and 8 weeks. Butterfat fed group showed high glucose levels at termination
3.5 Termination of animals and collection of tissues
At week eight the animals were terminated and the tissues were collected the details
are in Section 2.4.3. Feeding high fat diets led to the accumulation of subcutaneous
fat and abdominal fat for the rats on high fat diet. The images show the
accumulation of white adipose tissue with just traces of brown adipose tissue (BAT)
in the obese rats subcutaneously (Fig 3.5 A). The colour of the fat in lean rats that
were in the control group showed a brownish colour suggestive of BAT. The
abdominal area of the obese groups consisted of fat that seemed to be lining most of
the abdominal organs compared to the abdominal area of the control group that
showed very less obstruction from fat (Fig 3.5 B).
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A Subcutaneous fat B Abdominal fat
Figure 3.5: Accumulating fat tissue subcutaneously A and abdominally B
The accumulation of fat for the rats that were fed high fat diet was seen when rats were sacrificed. The
subcutaneous fat (A) was different with representative from the group on maintenance diet (left)
showing more of brown adipose tissue that the one from the group on high fat diet (right). Abdominal
fat (B) was more for the representative from the high fat diet group (right) compared to the one for the
maintenance diet fed group (left)
The weight contributed by fat in the total body weight was also seen in the adiposity
index as calculated using an equation: Adiposity Index = sum (fat pad)/ total body
weight X 100. The differences in adiposity index are shown in Figure 3.6. The group
that was fed on lard showed more weight contribution from stored fat compared to
the groups on chow (p<0.01). The other two groups on lard fat free and butterfat were
also fatter than the control group but less than the lard group (p<0.05). This might be
due to the differences in the storage of fat. On the other hand the fat was more on lard
that could contribute to the high energy stored as fat.
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Figure 3.6: Percentage weight contribution of fat to the total body weight (adiposity index)
The percentage fat mass contribution to the body weight (body mass index) was significantly high p <
0.001(***) for the lard fed group (L) compared to the group on maintenance diet (C). The butterfat (BF)
and the lard fat free (LF) fed groups had high adiposity index p < 0.01 (**) compared to the group on
maintenance diet.
Weighing the organs for both the diet induced obese rats and the control group
showed the significantly heavy fat tissues for the obese rats. The lard diet showed
significantly heavy fat pads (p<0.001). The other two groups on high fat diet were
also having heavy fat pads compared to the control but their fat pads were
significantly weighing less compared to lard group (p<0.05). There was no
significant difference in other organs those include liver, pancreas, adrenals, brain,
heart and spleen. The epidydimal, inguinal, retroperitoneal and perirenal fat were
compared in this study.
Four fat pads that were weighed and compared were significantly heavier for the high
caloric diets than that of the control group. The L diet fed group was having
significantly heavy epidydimal fat pad (p<0.01) when compared to the control group.
The BF and LF diet fed groups also showed to have significantly heavy epidydimal
fat pads than the control group (p<0.05). A similar trend was seen for the
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subcutaneous fat pads. The differences are shown in (Figure 3.7 A-D). The trend that
was shown by the retroperitoneal and perirenal fat pads were also showing  the
significant difference for the L diet fed group (p<0.01) to that of the control diet, with
significant difference between BF and LF fed groups when compared to the control
group (p<0.05).
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Figure 3.7: Comparison of fat pads for the groups on high fat diet to that of a control group
The figure shows the weights for epidydimal (A), inguinal (B), retroperitoneal (C) and perirenal (D).
The weights for the rats on high fat diets were compared to the weight of the rats on maintenance diet.
Fat tissue weights were significantly high for the lard fed group (L) p < 0.001 (***) compared to the
maintenance diet fed group (C). The lard fat free fed group (LF) and the butterfat fed group (BF)
showed significantly heavy fat tissue weights p < 0.05 compared to C group.
Adiposity index showed a similar pattern to the weight contribution of the fat pads.
The tissue weights were not significantly different Table 3.2 shows the weights. The
difference seen when analysing the fat tissue is not shown on tissue weight.
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Table 3.2: The mean tissue weights for the rats in different dietary groups at termination
Tissue C L LF BF
Liver (g) 13.91 ± 0.50 14.74 ± 1.28 13.63 ± 0.54 13.19 ± 0.42
Pancreas (g) 1.81 ± 0.13 1.61 ± 0.13 1.97 ± 0.19 1.84 ± 0.07
Kidney (g) 3.26 ± 0.10 3.00 ± 0.07 2.97 ± 0.08 2.93 ± 0.08
Adrenals (g) 0.035 ± 0.00 0.040 ± 0.00 0.040 ± 0.00 0.040 ± 0.00
Brain (g) 2.00 ± 0.05 2.01 ± 0.05 1.94 ± 0.04 1.97 ± 0.05
Heart (g) 1.41 ± 0.06 1.63 ± 0.09 1.40 ± 0.06 1.34 ± 0.05
Spleen (g) 0.81 ± 0.03 0.69 ± 0.07 0.79 ± 0.04 0.80 ± 0.02
3.6 Discussion
The monitoring of parameters that can contribute towards positive energy balance
entails measurement of a numerous aspects from food content to behaviour. As stated
before the obesity epidemic is in part attributable to global nutrition transition, that
sees the shift from the traditional plant-based foods to consumption of a more energy-
dense diet (rich in animal fat, sugar and processed foods), reduced fiber, and a rise in
sedentary lifestyles (Kimokoti and  Millen,  2011) there is  a need  for scrutiny in
studying obesity. The variation of dietary content is at the fore in the studies of
obesity. Previous studies report that fats promote overeating and the development of
obesity due to conversion of dietary fat to body fat at a low energy cost, high
palatability of high fatty foods and low satiation from fat, calorie for calorie, than
carbohydrates and proteins (Rogers, 1990).
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In the current study the same batch of chow was milled and the diets were prepared
for different groups to minimise variations. Because the fats that were used to prepare
diets differed especially for the BF diet, in which butterfat was employed in its
preparation, fatty acid analysis was performed. Compared to the control group the
high fat diet fed groups contained high saturated fats. The high fat diet fed rats has
been proven to increase body weight in many studies including the current study
(Sibuyi, 2009). Our diets had a common factor which is the high fat compared to a
similar study that focused on high fat low carbohydrate and a fat-sugar combination
diet compared to the standard chow diet for 24 weeks (Pritchett and Hajnal, 2011).
Both studies show high weight gain for rats on high caloric diet.
High protein diets have been found to reduce intake in days after starting feeding
them to rats followed by gradual but not complete return to normal energy intake
(Bensaïd et al., 2003). In most studies the high fat diet is the most studied diet, with
high protein diet and high carbohydrate even less common, hence the interest in
studying high fat diet because most of the complications have been identified using
high fat diet. Fatty acid content and the types of fatty acids contained in diets have
been of concern when studying obesity with studies proving the reduction of
circulating plasma free fatty acids with reduction in dietary fat content (McCarty,
1995). The plasma FFAs were not measured in this study, of which knowing the fatty
acid levels was going to be helpful especially when done together with insulin
measurements in identifying the fatty acid effect to insulin.
 
 
 
 
106
The plasma glucose levels in rats that were fed high fat diets did not differ
significantly to that of the control group. Glucose at baseline was the same for the
groups followed by the rise at day four. It is not clear why there was a rise because
this applied to the control group as well. At termination the glucose levels of the BF
fed group were high which can be the high content of saturated fed contained in the
diet. Previous studies have reported the high fat diets to induce obesity with glucose
levels not differing significantly to the control groups for diet induced obese rats
(Buettner et al., 2006). Despite the fasting and post-prandial glucose that is misleading
it has been proven that there is a glucose intolerance that kick starts as the intake of
high fat diet progresses (Lichtenstein and Schwab, 2000). These results were seen in
the studies where glucose tolerance and insulin tolerance tests were performed and
those were not done for the current study (Buettner et al., 2006).
Feeding high fat diet to rats results in the accumulation of fat which is reported by
many studies (Choi, 2010). Furthermore there is a dependency on the proneness of
the rat to develop obesity (Gao et al., 2002). In our study we considered resistance
to obesity by selecting high weight gainers to study them further. The studies
similar to our study considered both low weight gainers as means of studying
their source of resistance to obesity (Joo et al., 2011; Choi et al., 2010). The
contribution from fat is high for the high fat diet fed studies due to the reason that high
fat feeding promotes storage of fat.
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Weighing the fat pads distinguished between the high fat diets fed groups from the
control group to verifying that fat contributes a lot to the high body weights shown by
high fat diet fed groups. This is also reported in other studies that the long term
feeding of high fat diet, that is 8-14 weeks yield high adiposity indexes in rats
(Nascimento et al., 2011).
The diets used in this study showed different levels of obesity induction with high fat
deposition showed by the lard diet. In an unpublished study in our lab lard diet
showed to induce obesity for the female rats with protein malnutrition in their pups
that showed low body size and poor hair growth. The use of the fat free powdered
milk showed to have a difference in the pups’ body size. This shows that the diets can
contribute similar calories but dependent on the source the differences reflect in the
body structure. The LF and BF fed groups showed significantly low adiposity
indices compared to the L fed group. This could be possibly because of the calories
in the diets that they were given that contributed to increment in other tissues either
than fat tissue. Other organs that were weighed showed no significant difference.
Although the body composition was not determined in this study the body weights
were equal for the LF and L diet but different adiposity indices.
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Chapter 4: Visualization and PD Quest quantification of
differentially expressed proteins
4.1 Introduction
The emergence of proteomics as a discipline and a promising field is motivated by
the need for the understanding of proteins as the functioning machinery within a
biological system. Proteomics is has a potential of providing comprehensive
qualitative and quantitative information on all the proteins, something that cannot be
achieved using genomics or transcriptomics (Hebestreit, 2001). The closing of the gap
in information at protein level that has been seen when using the genes or mRNA
arrays is possible using proteomics since it is noticeable that the proteins are the ones
performing the functions downstream and the ones that can address the phenotypic
changes. An early diagnosis of obesity is required for timely interventions before the
condition kick starts and get to extremities.
Serum potentially carries an archive of important histological and molecular
information whose determination could serve to improve early disease detection
(Tirumalai et al., 2003b). The use of an animal model of diet induced obesity is at the
forefront of solving the obesity epidemic since the previous studies showed the
impact of obesity to be based on diet more than on genes as previously suggested
(Holemans et al., 2004). Caloric restriction still remains the most efficient way to
promote weight loss (Viguerie et al., 2005). Surely the p r o f i l e of the proteins
that runs in the blood can reveal information about the response post-translation
through the studying of plasma or serum. Using the diet to study obesity is the
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approach that will mimic closely the current situation in humans whereby people
increase the intake of energy with reduced dissipation of energy, than focusing on the
genes which are not likely to be causing such an increase in obesity pandemic. Genes
can be expressed highly only to lack the enabling environment for the translation to
take place. If the translation does takes place there are other forms that proteins
undergo such as post-translation, these changes can only be seen when looking at the
protein level. Proteomics is a discipline that enabled the creation of more knowledge
about the changes that are brought about by the role the proteins play in the
phenotype. With diet known to play a role in obesity development this study aims at
looking for the changes that take place in the proteome in relation to the diet and
time (changes that are brought by adiposity over time).
Serum proteins are a potential source of biomarkers. The challenge in the serum is the
number of proteins that are highly abundant while the other proteins are present in
low amounts. This calls for the depletion of high abundant proteins to make the
visibility of low abundant proteins to be enhanced. Various ways were available to
deplete abundant albumin those include methods that utilise high albumin affinity for
certain dyes such as Cibacron-Blue and derivatives thereof (Chen et al., 2005). Most
of the methods that are used for the depletion lack specificity and hence the study by
Chen, et. al. (2006) came with another perspective using trichloroacetic acid (TCA) a
known method of protein precipitation which is forming an organic solvent soluble
complex with albumin and acetone, which is the method that was adopted in the
current study with some modifications. This modified protocol was used in our serum
samples and keeping both the portions of samples to reduce the loss of information
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that can arise from throwing one portion of the precipitated sample. Both the portions
were analyzed using 1D SDS-PAGE and 2D SDS PAGE the same applied when
analyzing the gel images.
4.1.1 Reduction of sample complexity by depletion of highly abundant proteins
using TCA/acetone precipitation
Collected serum samples were processed using the TCA/acetone precipitation
method, see Section 2.5.1. Two sets of protein profiles were obtained and
separation of proteins using SDS PAGE showed a good resolution and distribution of
the bands in the albumin containing pellet (Figure 4.1 A). As shown in Figure 4.1 B
the separation was equally good in the albumin depleted pellet. The SDS PAGE for
C, L, LF and BF showed to be visually similar. This shows that with careful
preparation of samples the precipitation method yields comparable samples. The
processing of serum samples using  the TCA/acetone precipitation was applied
because it is a method that can be used by any lab because the solvents are easily
obtainable and are affordable.
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Figure 4.1: SDS PAGE albumin containing (A) and albumin depleted (B) serum sample from
TCA/acetone precipitation
TCA/acetone precipitation of serum results in two portions, one with albumin depleted (A) and one that
albumin rich (B). SDS-PAGE shows the profile for the groups on maintenance diet (C), lard diet (L), lard
fat free diet (LF) and butterfat diet (BF). A pre-stained Fermentas protein ladder was loaded in each gel
(M).
Splitting the proteome into two portions those are TCA precipitated and acetone
precipitated is showing to be even beneficial when running the 2D PAGE
electrophoresis. In Section 4.1.3 the separation of proteins in the 2D PAGE is discussed.
4.1.2 Analysis of protein concentration using Bradford method of protein
quantification
After processing  the serum samples the concentration of pellets obtained both
albumin containing and albumin depleted pellets were quantified using the Bradford
assay (Bradford, 1976), details are explained in Section 2.5.2. The concentrations for the
samples were extrapolated from the bovine serum albumin (BSA) standard curve
(Figure 4.2). The concentration of protein from albumin depleted sample was similar to
that of albumin containing sample. This is showing that abundance that has been
 
 
 
 
112
reported for albumin and globulins in the serum and plasma samples is indeed huge
enough to mask other proteins. Protein concentration was determined using the bovine
serum albumin (BSA) standard curve. The albumin containing sample showed to have
other proteins that precipitated with it with a possibility of some to be albumin binding
protein.
Figure 4.2: BSA standard curve representing the curves that were prepared for protein
concentration throughout the project
4.1.3 Analysis of TCA/acetone treated samples using 2D SDS-PAGE
The serum samples were separated based on their pI for the first dimension and based on
their molecular weight for the second dimension using the 2D PAGE (Section
2.5.4). Separating proteins using the 2D PAGE increased number of proteins that
can be visualized as shown by a number of spots. The gel with the albumin depleted
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sample contained many Coomassie visible spots (Fig 4.3. A), compared to the one with
albumin (Fig 4.3. B). Albumin occupied a biggest portion of the gel showing
albumin to contribute more to the concentration of the albumin containing pellet.
Some spots showed to be on the same molecular weight with continuous shift to the
side. This is mostly due to phosphorylation of proteins which affects the acidity of the
protein shifting it to alkaline direction. Both gels were used for image analysis to ensure
that the loss of information due to precipitation is minimized. If the 2D gels or SDS
PAGE were to be superimposed it shows that some proteins that appear better in the
albumin depleted sample would have been masked by albumin. The albumin
depleted and albumin containing sample is shown in Figure 4.3 A and B respectively.
Figure 4.3: 2D gel image showing albumin depleted (A) and albumin containing sample (B).
The spots labelled 1-5 are the spots that were differentially expressed in the albumin depleted serum
sample with obesity development (details in the following sections). The spot labelled 6 was differentially
expressed in the albumin containing sample.
M M
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4.1.5 Analysis of differentially expressed proteins using PD Quest software
Two-dimensional gel electrophoresis was used to separate the protein. After 2D gel
separation gels were stained with Coomassie brilliant blue and distained. Distained gels
were scanned using Pharox FX imager system and images were stored as
Quantity One images. The stored images were cropped and processed to prepare them
for the PD Quest analysis. Cropped images were loaded in the PD Quest software.
The scanner can be set to cover the scanning area based on the required information.
The replicates that were used per group were three from four dietary groups giving us
twelve gels in total Figure 4.4 page 113. Twelve gels (three replicates from each
dietary group) when subjected to PD Quest the number of Coomassie visible spots
were reported automatically by the software. A total of 154 spots were identified and
matched manually for the differential expression between control group and high caloric
diet fed groups. In the albumin depleted sample 64 spots were analyzed and 1 spot was
differentially expressed.
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Figure 4.4: 2D Gel images scanned for PD Quest analysis with three replicates per group.
Images showing the replicates in four rows with C fed group (top row), followed by BF, LF and L fed
groups respectively. Moving across are the best three representative gels from each group.
The same approach was used for the albumin containing pellet (Figure 4.5) where 12
gels that are consisting of three representative samples from each group were
scanned at once using the same filter, cropped and PD Quest analyzed. As shown in
the in Figure 4.4 the replicates that were used for analysis were scanned at once.
Scanning gels at once reduces the variation that can be found between the gels. The
same filter for PD Quest which is 2-fold was used for the identification of
differentially expressed proteins. Two spots at the same molecular weight were
identified to be up-regulated in the groups on high caloric diet from the albumin
containing sample.
C
L
LF
BF
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Figure 4.5: 2D gel images of albumin containing sample representative of four dietary groups.
Three replicates from each dietary group from left to right. The C diet replicates on the top followed by
the BF, LF and L diet replicates respectively. Samples were run on a 4-7 pH IPG strip, M stands for the
molecular     weight     marker     Fermentas     Page     Ruler     Unstained     Protein     Ladder.
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Analyzing the spot by comparing the intensities using PD Quest gave the output of
the spots that were two fold or more in intensity for high fat diet fed groups compared
to the control group. The data could be obtained in a scatter-plot format for each high
fat diet group compared to the control (Figures 4.6-4.8). The use of PD Quest is
making things easier for the data presentation. The scatter plot is presenting the data
visually with the spots that are outside the highest fold scale as the spots that are
beyond 2 fold different compared to the control group. The regression line is the one
that shows the similarity of the expression between the two groups.
For the easy tracing of the spot in question can also be presented as using the
histogram representing each replicate. Upon clicking on the spot the spot number on
the gel is labelled and that histogram gets presented. This is aiding in making sure
that the spot and the expression is not mistaken for different spots. The results have
been presented both on the scatter plot to show the number of spot that are beyond the
set limit of 2 fold and the histogram to show the expression per replicate. The
presentation on the histogram is also showing the number of replicates that were
highly expressing a particular protein and the quantity and the statistics are used to
determine if the protein is considered to be enhanced or suppressed in the test than in
the control group. The Figures 4.12-4.16 are representing such figures that show the
histogram presentation of the data.
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Figure 4.6: Scatter-plot showing the differences between spots for L fed group vs. control group.
Eleven spots that were identified to be quantitatively more than 2 fold different for the L fed group
compared to the C fed group. Spots outside the blue line (above) that is six spots are enhanced while
outside the red line (below) are five spots that were down regulated.
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Figure 4.7: Scatter-plot showing the differences between spots for LF diet fed group vs. control
group
The up-regulation of four spots seen for the lard fat free fed group when compared to the control
group, with down-regulation of five spots (spots below the red line). The middle line is the regression
line.
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Figure 4.8: Scatter-plot showing the differences between spots for BF fed group vs. control group
Four proteins were up-regulated in the butterfat diet fed group (spots above the blue line), with two
down-regulated proteins (spots below the red line) with the middle black line showing the regression
line.
The comparison between the HFD fed groups showed that the spots that were
differentially expressed for the L, LF and BF when compared to the C fed group are
also expressed differently amongst groups. The L fed group according to the dietary
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information is the group that contained the  highest contribution of fat derived
calories. The results in the previous chapter is showing the adiposity to be high for
this group and the two other groups on high fat diet to be having less adiposity as
revealed in the adiposity index. The L diet fed group compared to the LF fed diet
group showed two spots that are highly expressed, those were spot SSP 0001 and
SSP 7403. The expression of four spots was high in the L  diet fed group
compared to the BF diet fed group. One spot was less than two fold decreased in
expression in the L diet fed group compared to both LF and BF diet fed groups.
The LF and BF diet fed groups also show difference in the expression of the proteins
with four spots being highly expressed in the BF diet fed group. A single spot
was suppressed in the LF diet fed group. The scatter plots shows how the HFDs
fed groups compared are showed in the following figures. During the analysis Fat 1 is
corresponding to the L fed diet, with Fat 2 being the LF fed diet group and the Fat
3 is the BF fed diet group. The Figures 4.9, 4.10 and 4.11 are the scatter plot
representations of the groups‟ comparisons. The figures are showing the L and LF
comparison, followed by the L and BF comparisons and the third scatter plot is the
comparison of the LF and BF. The results are show that the expression is also
different between the high fat diets fed groups. The results reveal that the difference
in expression of a spot can be more than 2-fold for a particular HFD group compared
to the control with a chance of a 2-fold more expression when compared to HFD
group
 
 
 
 
Figure 4.9: Scatter-plot showing the comparison of spots expression for L and LF fed groups
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Figure 4.10: Scatter-plot of the L fed group compared to the BF fed group
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Figure  4.11: Scatter-plot presentation of the spots comparison between LF and BF fed groups
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The spots that were differentially expressed between the groups were identified
through clicking on the points that are beyond the limit (2-fold) on the scatter plot
and get directed to the spot as it appears with a spot number showing on the gel. The
following images show the spots that were found to be differentially expressed. To
make it even easier to follow results PD Quest present tabulated and graphical results
with markings on the gel images for an easy tracking of results. The protein identity
was then obtained through mass spectrometry analysis or using the 2D map for the
excision of spots for in-gel trypsin digests and mass spectrometry analysis. In the
current chapter the spots will be given numbers (1-6) and the identification of the
protein spots is discussed in the next chapter. PD Quest showed spot 1 (SSP 1101) to
be highly expressed in the control group.
The spot was showing to be reduced with obesity development. The expression of
SSP 1101 was very low to nearly fading on the 2D gel for the L group. The other two
groups were also having a less intense SSP 1101. The adiposity index is following the
same trend that was shown by the spot because as the adiposity index gets high the
expression of the spot is getting reduced. This spot could be a potential marker for the
fat deposition. Even the fat pads for the L group were heavier than that of all groups
which tells the weight of the whole animal to be contributed by the fat than the lean
body mass.
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Figure 4.12: The PD Quest outcome of the analysis showing the differential expression of spot 1
corresponding to SSP 1101
The top figure shows the representative control replicates and the master gel with the
spot that was analyzed marked with a yellow square. On the right hand side is the
histogram corresponding to the spot number showing the replicates‟ expression of the
protein from the four dietary groups. At the bottom are cropped images that show the
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reduction of the spot intensity with the most fading spot being the spot from the L
group and BF and LF also showing reduction of the spot 1 compared to the control
group.
The PD Quest results were giving the output as statistical and quantitative results.
The spots that were statistically significant and showing more than 2-fold difference
were considered. The expression of spot 2 (SPSS 7403) showed to be high for the
groups on high fat diet compared to the control group. The expression of spot 2 was
low for all the animals in the control group and a representative scatter plot shows this
(Figure 4.9).
 
 
 
 
129
Figure 4.13: Histogram PD Quest output of the differences in spot 2 expression in different groups which was
generated as SSP 6503
The spot that is analyzed is marked with a yellow square on the left pane of the
window, with a histogram highlighted on the right showing the SSP 6503 (spot 2)
expressions for C, L, LF and BF respectively. At the bottom are cropped images of
representative gels that show the appearance of the spot in four groups.
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The protein spots that were also up-regulated by feeding of high fat diet to the rats
were spot 3 (SSP 7403) and spot 5 (SSP 0001) shown in (Figure 4.10 and 4.11).
Figure 4.14: Figure 4.14: PD Quest results of the expression of spot 3 which had software generated number
as SSP 7403
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The spot number 7403 is shown on the master marked with a yellow square in all the gels
marking the spot. The right pane is showing the histogram presentation of the spot
expression. At the bottom are cropped representative images of the spots.
Figure 4.15: PD Quest results showing differential expression of spot 4 with software assigned number SSP
2501
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Figure 4.16: Figure 4.16: PD Quest analysis of the SSP 0001 (spot 5) with differential expression
showed in the cropped images
The spot from the albumin containing were analyzed as well for the differential
expression. One spot was more than 2-fold highly expressed for the groups that were
fed high caloric diets . The spot also proved that the keeping of the
albumin containing sample.   The results are shown in Figure 4.16 for PD Quest
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histogram result and the cropped images to show the representative spots per group
for the spot 0001. This spot was differentially expressed in HFD groups compare to
the control group with different intensities. The expression pattern followed the
adiposity indexes. The L diet fed group expressed the spot more than the LF
and BF fed groups. This spot could be  the potential spot for  the differentiation
of  the fat deposition which is the main identifier of obesity.
Discussion
Proteomics is promising great breakthroughs in the future based on the number of
protein related information that can be revealed in a single experiment. The impaired
protein synthesis in the muscle due to diet induced obesity shows the potential of the
proteomics in understanding body processes (Anderson et al., 2004). A study whereby
the imaging software was used to get variation of the results, reports that there are
variations even in two versions of the same analysis package after post hoc
analysis (Stessl et al., 2009). It is without a doubt that the plasma and other body
fluids have played a major role in quick prognosis and diagnosis of diseases, but the
majority of the findings were obtained while studying a single protein at a time.
The abundant proteins are the main concern in working with serum and this is the
main focus in improving the number of candidate proteins that can be used as
biomarkers. Albumin constitutes more than 50% of the total serum proteins, when
removed it enables the increase in protein loads on immobilized pH gradient (IPG)
gels with better visualization of low-abundance proteins, which may also result in the
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loss of other albumin-bound low-abundance proteins (Sahab et al., 2007). We used
the organic solvent precipitation approach and kept all the samples that result from
our precipitation to allow for the prevention of the loss of the albumin-bound
low-abundant proteins as covered above which was seen to be the case in the samples
where dyes are used for depletion of albumin. Pre-analytical variables have been
seen to be key  role players as well in the biomarker discovery in serum. The
study by Ahmad et al. (2009) reported the variation of spectral intensities of the
samples in relation to the storage time of the serum samples with the storage of
samples for 10 months being the longest time for serum. We performed our
proteomics work and identifications in less than 10 months which might be good for
the results obtained and the identifications through peptide mass fingerprinting.
The use of 2D PAGE came with solutions in the analysis of many proteins at once.
Iso-electric focusing (IEF) is having various pH gradients from narrow range to wide
range. There is improvement in the resolution of proteins with the use of the narrow
range strips because the narrow range is spreading over a greater physical distance
(Issaq and Veenstra, 2008b). This allows the separation of the proteins with a similar
pI to be separated with high resolution. Our study compared to the studies by Choi et.
al (2012) mentioned above have fewer proteins that were  identified to be
differentially expressed which can be contributed largely by the strip size that was
used in the studies. We used the mini strips, whereas they used the longer strips and
stained with silver stain which is a sensitive stain. This study is an initial stage to
finding the more responsive proteins in more than one diet. It also utilizes the widely
used laboratory material and affordable techniques for laboratories. Our findings are
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showing the proteins that are more obesity regulated than diet dependent proteins.
The spots that were revealed in the PD Quest analysis were found in the serum
depleted and serum rich portion. Previous studies usually use other methods of
depletion for abundant proteins. The proteins that were identified were below 200
kDa in the ladder. The identities of the spots that were differentially expressed are not
known without the spots being identified.
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Chapter 5: Identification of proteins by MALDI-TOF MS
Introduction
The utilization of image analysis for quantification of protein expressions in-gel is a
powerful tool to show the proteins that are responsive during the diseased state or an
unpleasant condition development. The number and the level of response of protein
spots are not enough and they give limited information unless the spots are identified
so as to get more details of the proteins identified in conjunction with the disease
in question. The success of 2D-PAGE in separating the proteins came with
challenges including identification. The identification of proteins over time was
achieved by co migration of sample with purified protein or blotting as the main
methods (Rabilloud et al., 2010). The use of Edman’s sequencing has been a gold
standard for a long time but the protein to be identified need to be pure which is not
accommodating 2D-PAGE proteins because of quantities required for analysis.
The numbers of proteins that are to be identified are usually high because 2D gel
resolves even more proteins. This then require an increase in the identifications that
can be made in a short space of time. The use of mass spectrometry is at the core of
analysis and the accumulation of results is enhanced through mass spectrometry.
MALDI TOF mass spectrometers are the most commonly used for their relative ease
of use enabling even a non-specialist lab to readily access the technology for
biomolecular analysis e.g. protein identification through peptide mass fingerprinting
(PMF) (Zanders et al., 2012). Proteins at their femtomole quantities can be identified
following the excision of the protein from the gel, washing and destaining, reduction
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and alkylation, in-gel trypsin digestion, MALDI TOF MS of the tryptic peptides and
database searching of the PMF data. This method can manually process up to 96
proteins at once (Zanders et al., 2012). This is showing an improvement that is of
benefit to clinical studies as well that will bring high throughput.  Versatility of
MALDI TOF MS is recognised across different platforms that utilize the technology.
In the chromosome analysis it is able to distinguish the difference in genes even if the
difference is a single nucleotide (Hahn et al., 2008).
In the current study the proteins that were found to be differentially expressed
(Chapter 4) were subjected to the MALDI TOF analysis and four proteins were
successfully identified. There were proteins were not identifiable but those proteins
were identified from the serum proteome map (Gianazza et al., 2002b). The identified
proteins were searched for further information on databases. The results for the
MALDI TOF analysis and the outcomes are discussed in the following sections. The
identification of proteins was validated using the Western blot. The validation and the
bioinformatics data mining are reported in chapter 6. The current chapter covers the
PMF and map identified proteins.
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5.1 Analysis of in-gel digested proteins using MALDI TOF MS and reference map
The spots that were identified to be differentially expressed (Chapter 4) were excised
and in-gel digestion followed by identification (performed as detailed in Section
2.5.7). The identification of protein has improved since the use of mass
spectrometry. In this study we used matrix assisted laser desorption/ionization time
of flight (MALDI-TOF MS) for peptide mass fingerprinting. The proteins that were
considered for identification were five in the albumin depleted sample and two spots
in the albumin containing sample. Three spots in the albumin depleted sample were
identified to be Hemopexin, alpha 1 macroglobulin and C-reactive protein. The other
two proteins could not be identified. The mass spectra and amino acid sequences are
shown in (figure 5.1-5.4).     Apolipoprotein AIV was identified for the two spots
that were excised from the albumin rich sample.
The identification of the proteins by  MALDI-TOF was performed on digested
peptides with an aid of the database searches to match the peptides. The MASCOT
database was used with consideration of the identities that have the high MOWSE
score. The identified peptides (matched peptides) are shown in red in the sequence as
given with every spectrum in the results section. This section shows the outcome of
the MALDI-TOF MS in identification of the in-gel digested proteins from the spots
that were identified to be differentially expressed in the high caloric diet fed rats.
The identifications were corresponded with the 2D maps on serum that were
published before. The study on inflammation (Giannaza et. al (2002) that used serum
that contained most of the proteins labelled was considered for the identification of the
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proteins that were not identifiable using MALDI-TOF MS. The confirmations of
the proteins identified were performed using Western blot and the results are
contained in the next chapter.
In the depleted sample the proteins that were identifiable using mass spectrometry
were three in total. The other two proteins were identified from the 2D map as
explained above seeing the matching of the mass spectrometry identified proteins
with the identities on the map. Mass spectrometry identified proteins include the
hemopexin (Figure 5.1).
1 MARTVVALNI LVLLGLCWSL AVANPLPAAH ETVAKGENGT KPDSDVIEHC
51 SDAWSFDATT MDHNGTMLFF KGEFVWRGHS GIRELISERW KNPVTSVDAA
101 FRGPDSVFLI KEDKVWVYPP EKKENGYPKL FQEEFPGIPY PPDAAVECHR
151 GECQSEGVLF FQGNRKWFWD FATRTQKERS WPAVGNCTAA LRWLERYYCF
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201 QGNKFLRFNP VTGEVPPRYP LDARDYFISC PGRGHGKLRN GTAHGNSTHP
251 MHSRCNADPG LSALLSDHRG ATYAFSGSHY WRLDSSRDGW HSWPIAHHWP
301 QGPSAVDAAF SWDEKVYLIQ GTQVYVFLTK GGNNLVSGYP KRLEKELGSP
351 PGISLDTIDA AFSCPGSSKL YVTSGRRLWW LDLKSGAQAT WAELSWPHEK
401 VDGALCLEKS LGPYSCSSNG PNLFFIHGPN LYCYSSIDKL NAAKSLPQPQ
451 KVNSILGCSQ
Figure 5.1: Mass spectrum and amino acid sequence for hemopexin
The coverage for hemopexin was good and the peak intensities shows to be good. The length of the
matched peptides (red) shows the good coverage and the MOWSE score was high for hemopexin
compared to other MASCOT returned identities
The other excised protein spot was identified to be alpha 1 macroglobulin-like protein
because it was not validated using Western blotting with the spectrum and the
sequence as shown in (Figure 5.2). The peptides that were matched were few but the
coverage was good. The identified protein was the precursor which is found at a
lower molecular weight because alpha 1 macroglobulin is having a high molecular
weight but the excised spot was at a lower molecular weight, suggesting it was a low
molecular weight fragment of alpha 1 macroglobulin.
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1 MRRNQLPIPV FLLLLLLLPR DATAATGKPR YVVLVPSELY AGVPEKVCVH
51 LNHLNETVTL NVTLEYGVQY SNLLIDQAVD KDSSYCSSFT ISRPLSPSAL
101 IAVEIKGPTH HFIKKKSMWI TKAESPVFVQ TDKPIYKPGQ TVKFRVVSVD
151 ISFRPVNETF PVVYIENPKR NRIFQWQNVD LPGGLHQLSF PLSVEPALGI
201 YKVVVQKDSG KKIEHSFEVK EYVLPKFEVQ VKMPKTMAFL EEELVVTACG
251 LYTYGKPVPG LVTMKVCRKY TQSYSNCHGQ HSKSICEEFS KQADEKGCFR
301 QVVKTKVFQP RQKGYDMKIE VEAKIKEDGT GIELTGTGSC EIANTLSKLK
351 FTKANTFYRP GLPFFGQVLL VDEKGQPIPN KNLTVQVNSV RSQFTFTTDE
401 HGLANILIDT TNFTFSFMGI RVIYKQNNIC FDNWWVDEYH TQADHSAARI
451 FSPSRSYIQL ELVLGTLACG QTQEIRIHFL LNEDALKDAK DLTFYYLIKA
501 RGSIFNSGSH VLPLEQGKVK GVVSFPIRVE PGMAPVAKLI VYTILPNEEL
551 IADVQKFDIE KCFANTVNLS FPSAQSLPAS DTHLTVKATP LSLCALTAVD
601 QSVLLLKPEA KLSPQSIYNL LPQKAEQGAY LGPLPYKGGE NCIKAEDITH
651 NGIVYTPKQD LNDNDAYSVF QSIGLKIFTN TRVHKPRYCP MYQAYPPLPY
701 VGEPQALAMS AIPGAGYRSS NIRTSSMMMM GASEVAQEVE VRETVRKYFP
751 ETWIWDMVPL DLSGDGELPV KVPDTITEWK ASAFCLSGTT GLGLSSTISH
801 KVFQPFFLEL TLPYSVVRGE AFILKATVLN YMPHCIRIHV SLEMSPDFLA
851 VPVGSHEDSH CICGNERKTV SWAVTPKSLG EVNFTATAEA LQSPELCGNK
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901 VAEVPALVQK DTVVKPVIVE PEGIEKEQTY NTLLCPQDAE LQENWTLDLP
951 ANVVEGSARA TQSVLGDILG SAMQNLQNLL QMPYGCGEQN MVLFVPNIYV
1001 LEYLNETQQL TEAIKSKAIS YLISGYQRQL NYQHSDGSYS TFGDRGMRHS
1051 QGNTWLTAFV LKAFAQAQSY IYIEKTHITN AFNWLSMKQR ENGCFQQSGS
1101 LLNNAMKGGV DDEVTLSAYI TIALLEMPLP VTHSVVRNAL FCLETAWASI
1151 SNSQESHVYT KALLAYAFAL AGNRAKRSEV LESLNKDAVN EEESVHWQRP
1201 KNVEENVREM RSFSYKPRAP SAEVEMTAYV LLAYLTSASS RPTRDLSSSD
1251 LTTASKIVKW ISKQQNSHGG FSSTQDTVVA LQALSKYGAA TFTKSNKEVS
1301 VTIESSGTVS GTLHVNNGNR LLLQEVRLAD LPGNYITKVS GSGCVYLQTS
1351 LKYNILPEAE GEAPFTLKVN TLPLNFDKAE HHRKFQIHIN VSYIGERPNS
1401 NMVIVDVKMV SGFIPVKPSV KKLQDQSNIQ RTEVNTNHVL IYIEKLTNQT
1451 MGFSFAVEQD IPVKNLKPAP VKVYDYYETD EFAIEEYSAP FSSDSEQGNA
1501
Figure 5.2: Mass spectrum and amino acid sequence for Alpha 1 macroglobulin
Few peptides matched for alpha 1 macroglobulin (red) but the coverage was enough to give an identity
of the protein
The third identification in the albumin depleted sample was C-reactive protein. The
identity  was taken based on the MOWSE score and the peptide coverage. The
matched peptides are showing to be found evenly distributed in the sequence as
shown (Figure 5.3).
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1 MYRIATKTWH VQVLFVYSVP GSSALFAGVP AALLHALVLW LLSSVEAIAT
51 LLSLVLYSFH DASSVHSCQV IPSEADSGFV NYIKAMIWEK ELLLKGDLNH
101 SEADELGAKQ ALALGAYRLL ISPRWGVYRK EGGTQDPNNI KYLGVTLTKQ
151 VKDLYNKNFK TLKKEIEEDL RRWKDLPCSW IGRINIVKMP ILPKAIYRFN
201 AIPIKIPIQF FKELDRTICK FIWNNKKPRI AKAILNNKRT SGGITIPELK
251 QYYRAIAIKT AWYWYRDRQI DQWNRIEDPE MNPHTYGHLI FDKGAKTIQW
301 KKDSIFSKWC WFNWRSTCRR MQIDPCLSPC TKLKSKWIKD LHIKADTLKL
351 IEEKLGKHLE HMGTGKNFLN KTPMAYALRS RIDKWDLIKL QSFCKAKDTV
401 VRTNRQPTDW EKIFTNPTTD RGLISKIYKE LKKLDRRETN NPIKKWGSEL
451 NKEFTAEECR MAEKHLKKCS TSLVIREMQI KTTLRFHLTP VRMAKIKNSD
501 DSRCWRGCGE RGTLLHCWWG CKLVQPFWKS VWRILRKLDI ELPEDPAIPL
551 LGIYPKDAPT YKKDTCSTMF IAALFIIARS WKEPRCPSTE EWIQKMWYIY
601 TMEYYSAIKN NDFMKFVGKW LELENIILSE LTQSQKDIHD MSKQAFVFPG
651 VSATAYVSLE AESKKPLEAF TVCLYAHADV SRSFSIFSYA TKTSFNEILL
701 FWTRGQGFSI AVGGPEILFS ASEIPEVPTH ICATWESATG IVELWLDGKP
751 RVRKSLQKGY IVGTNASIIL GQEQDSYGGG FDANQSLVGD IGDVNMWDFV
801 LSPEQINAVY VGRVFSPNVL NWRALKYETH GDVFIKPQLW PLTDCSQVQV
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851 GQRPPHKTDT LKLIEEKVGK NLGHMGTGPH EAQEGKTKVW MLQSFLEGGT
901 KILTGGNMER KCGIEERPSR DCPTWGSSPH SATKPRQHCG YQEVHADRNL
951 IQLSPERLCQ SLTNTEVDAH SQPLTEKEVP NGGVREKTEG VEGVCNPIRR
1001 TVSSNQPYPV RDPRD
Figure 5.3: Mass spectrum and amino acid sequence for C-reactive protein
The peaks that are found in the spectrum have high intensities. The distribution of matched peptides
(red) from the sequence is even.
The protein that was identified to be differentially expressed in the albumin
containing sample of the TCA/acetone precipitated serum was identified to be
apolipoprotein AIV (Figure 5.4). The protein that was having a highest MOWSE score
was chosen and it contained the highest peptide coverage. It was corresponding with the
molecular weight of the spot that was excised for digestion at 46 kDa. The spots that were
excised were side by side and both were identified to be Apo AIV.
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1 MFLKAVVLTV ALVAITGTQA EVTSDQVANV MWDYFTQLSN NAKEAVEQLQ
51 KTDVTQQLNT LFQDKLGNIN TYADDLQNKL VPFAVQLSGH LTKETERVRE
101 EIQKELEDLR ANMMPHANKV SQMFGDNVQK LQEHLRPYAT DLQAQINAQT
151 QDMKRQLTPY IQRMQTTIQD NVENLQSSMV PFANELKEKF NQNMEGLKGQ
201 LTPRANELKA TIDQNLEDLR SRLAPLAEGV QEKLNHQMEG LAFQMKKNAE
251 ELQTKVSTNI DQLQKNLAPL VEDVQSKLKG NTEGLQKSLE DLNKQLDQQV
301 EVFRRAVEPL GDKFNMALVQ QMEKFRQQLG SDSGDVESHL SFLEKNLREK
351 VSSFMSTLQK KGSPDQPLAL PLPEQVQEQV QEQVQPKPLE S
Figure 5.4: Mass spectrum and amino acid sequence for apolipoprotein AIV
The mass spectrum generated and the sequence that was retrieved from MASCOT database showing
the matched peptides in red. The spectrum also shows the intensity of the peaks as plotted against the
mass to charge ratio (m/z) for peptides.
The proteins that were identified are further tabulated (Table 5). The table is giving
details of identified proteins. The accession number entry name and the gene that
encode the protein are given in the table. The sequence coverage is also given on the
table in percentages which shows the sensitivity of the MALDI TOF in identifying
the peptides that belongs to a certain protein. There are even proteins that have a low
coverage  like the C-reactive  protein that was identified to have eight percent
coverage. There other two proteins marked with the RMI standing for the reference
map identified proteins were taken from the reference map that was published in the
inflammation study (Giannaza et. al (2002) and the 2D from a control was used for
such identifications.
The use of the reference map in the current study was due to the MALDI TOF MS
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not generating the spectra for the proteins. The map adopted from the inflammation
study was used for the identification of the rest of the proteins (Gianazza et al.,
2002a). The map was similar to the gel image that was seen for this study (Chapter 4)
but there were more proteins above pI 7 because a different IPG strip was used, which
is a pI 3-10 compared to the pI 4-7 used in this thesis. The proteins were then mapped
according the information showed in the map. The map shows the mixed sample with
albumin available in the map. In this study we separated the abundant proteins from
the less abundant proteins and improved the resolution of the proteins. The map aided
in identification of Fetuin A and Fetuin B which are proteins that were also
differentially expressed but were not identifiable with the mass spectrometry.
Figure 5.5: 2D map of a rat serum taken from Gianazza, et. al., 2002
 
 
 
 
Table 5: Peptide mass fingerprinting of differentially expressed spots
Spot no. Protein Accession
no.
Score Theoretical
PI
In gel PI Sequence
Coverage
Regulation
on HFD
Theoretical
MW (kDa)
In gel
MW(kDa)
1 Alpha 1 Q63041 67 6.46 4.9 8 165 ~40
Macroglobulin-like
2 (RMI) Fetuin A P24090 - 6.05 5.15 - 59 ~85
3 (RMI) Fetuin B Q9QX79 - 6.71 6.0 - 41.5 ~70
4 Hemopexin-like Q5BKB4 77 7.58 5.85 25 53 ~100
5 C-reactive protein
precursor
A42579 51 4.89 4.6 8 25.4 ~30
6 Apolipoprotein LPRTA4 84 5.12 5.1 33 44 ~45
AIV
RMI- reference map identified proteins with the information that is available obtained from uniprot search not NCBI
147
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5.6 Discussion
The use of the proteomics approach to identify the changes at protein level is a
promising to be a potential approach to giving the clues to the questions that arise
from the disease development. Clinical breakthroughs brought about by proteomics
have been seen. MALDI-TOF MS ’ s clinical breakthrough that showed to be
clinically successful is the use of MALDI-TOF in many routine clinical microbiology
laboratories as a routine microbial profiling tool (Lescuyer et al., 2010). Another
study using LC-MS to study protein differences in tissues showed that there are
differences in the tissues for the mice that are fed high fat diet to the proteins
expressed by the mice fed low fat diet. The study focused o n skeletal muscle and
liver which made them report their  observations that feeding leads to
accumulation of  skeletal muscle which was noticeable when they looked at fasted
rats compared to the fed rats (Anderson et al., 2004). Studying the tissues is an
invasive way of obtaining the information but this study also reported that they
observed the increase in plasma albumin levels. The use of the body fluids with less
invasive approach like serum and plasma  to non-invasive  methods like  the use of
urine and saliva are of interest because they can enhance the delivery of
biomarkers while encouraging the response from patients. The study on serum and
plasma has been reported more in cancer research with some accumulation of the
studies on obesity, but there is still a need to interrogate the proteome complexion in
both serum and plasma in relation to obesity development because it can aid much in
the identification of the role players and possible ways to intervene.
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The numbers of spots that can be found to be differentially expressed are dependent
on various parameters. The preparation of the sample to the stain that is used is also
has an effect on the visibility of the spots. In the serum there are variations in the
number of spots that are getting identified by different studies. The study by Zhao, et.
al. (2008) identified seven proteins with one unnamed protein. The verification was
performed for alpha 1 macroglobulin which showed to be down- regulated with
obesity development. The studies by Choi, et. al. (2010 & 2012) showed differences
in the serum proteome that is due to obesity and the differences that are gender based
obesity proneness or obesity resistance.
The software used in studies to analyze the images is uses the similar principle of
matching the spots with a master gel created as a reference gel. The studies above
used UMAX Powerlook 1120 instead of Quantity One used in the current study.
After the images were produced ImageMaster 2D software was used contrary to the
use of PD Quest in our study. There have been reports of the variation between labs
when it comes to the Proteomics finding which led to the Human Proteome
Organization (HUPO), which tried to set the standards when it comes to procedures
to use across the labs for human serum proteome. The identities show that there are
common spots that have been found to be obesity associated in the current study and
in the studies mentioned above. The spots that were identified in our study are the
spots that responded to the increase in calories across the groups because those
were the spots that were associated with obesity than a particular diet.
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The serum map that has been produced in the study on inflammation by Gianazza., et.
al. (2002b) is still having the similar pattern as other maps in the studies that are
recently published including the current study. The map was similar to the gel image
that was seen for our study but there were more proteins above pI 7 because a
different IPG strip was used, which is a 3-10 compared to the 4-7 used in this thesis.
The proteins were then mapped according the information showed in the map. The
map shows the mixed sample with albumin available in the map. In this study we
separated the abundant proteins from the less abundant proteins and improved the
resolution of the proteins. The map aided in identification of Fetuin A and Fetuin B
which are proteins that were also differentially expressed but were not identifiable
with mass spectrometry.
Although the maps in the inflammation studies and the obesity study may have
different proteins that are deregulated between the normal and acute phase the
reference maps of the serum control are reliable for the identification of the spots that
are unidentifiable with the mass spectrometer and hence the use of the reference map
for identification of some unidentifiable proteins. The use of 2D for analysis of rat
serum provides a reliable way to monitor the onset or progression of pathological
state that is inflammatory component involving, furthermore it also aids in assessing
the outcome of any therapeutic intervention (Gianazza et al., 2012).
The identities that were found in the current study are show the proteins that are
responsive to the development of obesity because the body mass indexes are high for
all the rats that were fed on high caloric diets. The down-regulated protein was also
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common and this gives the indication that these proteins may be potential markers for
acute obesity development. Unlike other studies the current study is showing the use
of the lard diet that is widely used together with other diets to show that the high
caloric intake is not only referring to lard but to other diets. The regulation above 2-
fold for the group on high caloric diets compared to the control shows that the
identified proteins are highly responsive to accumulation of fat stores.
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Chapter 6: Validation of proteins’ differential expression through
Western blot and bioinformatics of analyzed proteins
Introduction
The analysis of gel images and spots comparison through software is an important
step towards identifying the spots that are differentially expressed between a normal
and a diseased sample. The results obtained from such analysis always call for
verification. Western blot is the widely used procedure for the verification of the
expression of proteins and it is sensitive enough to pick up the proteins in
picogram scale. This allows the use of Western blot to compare the intensity of bands
as well as the confirmation of spots on a 2D PAGE. Studies where proteomics tools
are used to verify protein expression in serum include studies in cancer (Villanueva et
al., 2005), nutrition (Kumar and Mann, 2009), diabetes (Sundsten and Ortsäter, 2009),
obesity (Zhao et al., 2008) and there are a lot other studies that utilize serum to
identify differentially expressed proteins.
The use of Western blot as a method of verifying the proteomics results has been used
by most of the researchers with ELISA being another method when Western blot is
not used (Zhao et al., 2008). ELISA is having a challenge of being costly compared
to Western blot which allows repetitions and a room of troubleshooting. The use of
antibodies in Western blot also poses a challenge because they are expensive but with
the use of Coomassie stain for  internal control (Welinder and Ekblad, 2010)
this promises to keep Western blotting as a preferred method of verification.
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When proteomics results have been verified there is a need of giving a biological
meaning using bioinformatics. Bioinformatics is defined as a mean for functional
analysis and data mining of data sets leading to biologically interpretable results and
insights (Kumar and Mann, 2009). Bioinformatics was used in this study for protein
identifications to mining the information that is readily available in order to find their
association with obesity. This completes the understanding of the proteins and their
functionality. Proteomics in conjunction with bioinformatics makes the success in
high throughput data generation and answering of questions that arise regarding the
differences between the diseased and normal state.
The combination of proteomics and bioinformatics is growing at a high speed. The
ever improved proteomics approach is currently enabling the increase in the
throughput while bioinformatics effort in completing the proteomic findings. The
collection of data with obesity genomic loci from different species such as human,
cattle, rat and mouse from a gene atlas, which includes a database and genomic view
(Kunej T, 2012) shows the effort in trying to narrow the data and cut repetitions
towards better understanding of obesity.
6.1 Western blot validation of the differential proteins identified using proteomics
The results obtained using the proteomics image analysis software can be confirmed
using other protein quantification methods. The most sensitive methods which are
ELISA and Western blot are usually methods of choice for their high sensitivity and
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accuracy in determining the expression of protein. As a method to validate the results
obtained in proteomics analysis we used Western blotting because it is worth
considering the technical errors and other shortcomings in proteomics analysis.
Western blot analysis was performed on the four proteins that were differentially
expressed. Transferrin (TFR) was used as a loading control loading control. A study
by Wilkins et. al. (2005) shows that transferrin levels do not change in the blood
despite the disease state. There was a struggle in getting  hold of commercial
alpha 1 macroglobulin. Hemopexin was also not validated using the W estern
blotting even though the results could show the enhanced expression of the
hemopexin spot on the gel.
When analyzing the Western blot for apolipoprotein AIV expression, there was a
significant increase in the amount of apolipoprotein AIV in high caloric diet fed
groups compared to the control group. The group on the L diet was having
significantly  high apolipoprotein AIV (p<0.01), but it was having less levels
compared to LF and BF diet fed groups with highest expression seen in the BF fed
group. The expression of apolipoprotein AIV has been found to be not too high with
high caloric diets in some studies with high levels reported in other studies. The
outcomes from the plasma and serum studies of apolipoprotein AIV are discussed
further in section 7.1 where details are given with literature that has been looked at.
There is no other lipoprotein that was identified to be commonly responsive to high
caloric diet in this study.
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Figure 6.1 Figure 6.1 Western blot validation of apolipoprotein AIV showing a significantly low
expression by the chow fed group (control)
The figure shows significantly high expression for the lard (L), lard fat free (LF) and butterfat (BF) fed
groups compared to the maintenance (C) diet fed group. ** (p < 0.01); *** (p < 0.001)
The CRP has long been associated with inflammation. There is little information that
link CRP to obesity. The association of CRP with obesity is rising from the results
that have recently been reported and the discussion section contains details on this. In
this study Western blotting confirmed the results that were obtained in proteomics
study. Feeding high caloric diets increased the levels of CRP significantly (p<0.01).
The highest expression was seen in the group that was fed L diet. There were
similar expression levels for the BF and LF fed groups.
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Figure 6.2: Western blot validation of PD Quest results on C-reactive protein
The expression of C-reactive protein (CRP) in serum for the rats that were fed high fat diets compared to
the rats that were fed maintenance (C) diet. Lard fed group showed significantly high levels of CRP
compared to C fed group p < 0.001 (***). The lard fat free (LF) and butterfat (BF) fed groups had high
levels of CRP p < 0.01 (**) compared to C fed group. Transferrin (TFR) was used as a loading control.
Fetuin A increased with increase in caloric intake resulting in significantly high levels
(p<0.05) for groups fed high caloric diets. The levels were high in L and LF fed
groups. The results on fetuin A confirm the results that were obtained when using PD
Quest to analyze the spot intensities for the high caloric diet fed groups compared to
the C fed group (control group). The role of fetuin A in insulin resistance has been
reported in studies that were focusing on the role the protein plays in the body. The
effect of increase in fetuin A is not having established evidence in this study that it
triggered insulin resistance or not as the glucose levels were shown not to be
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significantly different in section 3.3.2 where glucose measurements were shown. The
high levels of fetuin A could have been identified to be linked with insulin if insulin
levels were included in the current study but insulin levels were not measured.
Figure 6.3: Validation of the Fetuin A by Western blot for the expression between the groups
Western blot validation shows the up-regulation of Fetuin A (Fet A) for the lard (L), lard fat free (LF)
and butterfat (BF) compared to maintenance (C) fed group p < 0.05 (*). Transferrin (TFR) was used as a
loading control.
Fetuin B which is another protein from the Fetuin family was identified to be highly
expressed when high caloric diet was used to induce obesity in rats. The levels were
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showing to be increasing with the increasing fat content of the diet. This was seen
with high levels of Fetuin B seen when performing Western blotting in L, LF, and BF
when compared to C. The levels were high for the three high caloric diet fed
groups (p<0.05). When compared to C there were high levels for BF with more levels
in LF and L of Fetuin B based on the Western blot analysis.
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Figure 6.4: Fetuin B expression at termination
Significantly high expression of Fetuin B (Fet B) for the butterfat (BF) fed group p < 0.05 (*); lard fat
free (LF) and lard (L) fed groups p < 0.01 (**) compared to maintenance (C) fed group. Transferrin
(TFR) was used as a loading control.
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6.2 Bioinformatics analysis of differentially expressed proteins
Bioinformatics is a discipline on its own. The utilization of bioinformatics in various
studies is assisting with the utilization of the readily available information. This
speeds up the generation of the information  with an aid  of centralizing  the
information that is known. Bioinformatics helped in finding the information about the
proteins identified quicker. Expasy was used to get most of the information about the
proteins from the UniProt database in this study. The proteins that were searched from
UniProt are shown in table 6.1. The three dimensional structure of proteins were
taken from the protein model portal (PMP) database. The structures shown are the
cartoon model and the structure with the highest percentage identity. The KEGG
helped in the orthologs study of the proteins in order to find the role that proteins
might have in the metabolic pathways.
The information written about the proteins is the same information that is contained
in the Uniprot database. Some of the information is not experimentally based
information. It is a result of the various similarities that is identified from the protein
in the same family or with the similar conformation. An approach to use the KEGG
aids in creating the understanding of the role played by proteins in the pathways. It is
worth mentioning that some of the proteins did not have any link to pathways even
with the use of orthologs. Proteins have different functions and it is expected that
while some are functional proteins others are structural proteins or just helping in
other functioning either than pathways. The utilization of bioinformatics enhances the
identification of proteins to diseases. In this study the orthologs were employed to
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identify the pathways where proteins that were differentially expressed play a role
based on the structural similarity of proteins and the possibility of the proteins acting
on similar substrates as the proteins of similar structure with readily available
information.
6.2.1 Bioinformatics review of alpha 1 macroglobulin
Alpha 1 macroglobulin (A1M) is a disulfide linked homotetramer existing as a 165
kDa subunit that is cleaved to a 45 kDa subunit. It is encoded by A1m gene also
known as Pzp gene. It is made up of 1500 amino acids and it is completely
sequenced. Alpha 1 macroglobulin is a serine protease inhibitor. The function by
similarity (not known through experiments) as found in the Uniprot database is
inhibition of all four classes of proteinases by a unique „trapping‟ mechanism. The
protein has a peptide stretch called ‘ bait region’ which contains specific cleavage
sites for different proteinases. When a proteinase cleaves the bait region, a
conformational change is induced in the protein which traps the proteinase. The
entrapped enzyme remains active against low molecular weight substrates; activity
against high molecular weight substrates is greatly reduced. Following cleavage in
the bait region a thioester bond is hydrolized and mediates the covalent bonding to the
proteinase.
Performing orthologs revealed that there are similarities between the structures of
alpha 1 macroglobulin and alpha 2 macroglobulin. The structures as obtained
using the protein model portal (PMP) showed to be similar as shown in figure 6.5.
The competition experiments using rat receptor binding domain of alpha 1
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macroglobulin and labelled human alpha 2 macroglobulin, revealed that recombinant
version of rat alpha 1 macroglobulin have a high affinity for alpha 2 macroglobulin
receptor as the 40 kDa light chain for alpha 1 macroglobulin (Nielsen et al., 1995). In
this study the conclusion was that macroglobulins interaction is determined by the C-
terminal residue which is approximately 150 residues. In the complement and
coagulation cascade alpha 1 macroglobulin is said to play a similar role as alpha 2
macroglobulin (red) in Figure 6.6 which is to inhibit the proteases. As one of the
serine protease inhibitors the alpha 1 macroglobulin can inhibit the serine proteases
from being triggered by either extrinsic or intrinsic pathways as they required for
blood coagulation (Norris, 2003). The reduction in the expression levels of alpha 1
macroglobulin with development of obesity could be a contributor to atherosclerosis
but that is not proven since currently there is limited information on alpha 1
macroglobulin.
A B
Figure 6.5: Alpha 1 macroglobulin (A) and alpha 2 macroglobulin (B)
The two proteins show structural similarities and they have been shown to have
affinity for the same substrate. Based on the studies that have been done on alpha 2
macroglobulin it has been suggested that alpha 1 macroglobulin can have similarity in
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function with alpha 2 macroglobulin in red (Figure 6.6). In the figure alpha 2
macroglobulin inhibits a number of proteases that are crucial to the coagulation
pathway. The current study is not going to get into details in the pathways as this was
not part of the study purpose but as a way of identifying the pathways and the roles of
proteins in those pathways.
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Figure 6.6: complement and coagulation cascade (KEGG pathways)
6.2.2 Bioinformatics review of apolipoprotein AIV
Apolipoprotein AIV (Apo A4) is a 391 amino acid long protein encoded by the
ApoA4 gene. It functions in chylomicrons and VLDL secretion and catabolism. It is
also required for efficient activation lipoprotein lipase by Apolipoprotein C-II; potent
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activation of LCAT. Apo A4 is a major component of HDL and chylomicrons
secreted to the plasma. It contains nine of thirteen 22-amino acid repeats (each
22mer is actually a tandem array of two, A and B, related 11mers) occurring in this
sequence that are predicted to be highly alpha-helical and many of these helices
are amphipathic. They may therefore serve as lipid binding domains with lecithin
cholesterol acyltransferase (LCAT) activating abilities.
Apolipoprotein is reported to be orthologous to apolipoprotein AI. Both proteins are
lipid carrier proteins. The production of lipoproteins can be triggered by the
accumulation of very low density lipoproteins (VLDL) and chylomicrons as shown in
the pathway (figure 6.8) showing the chronology of processes taking place leading to
more lipid transport proteins being produced.
A B
Figure 6.7: Apolipoprotein AIV and apolipoproteinAI
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The accumulation of the apolipoprotein AI is shown in the pathway of which
apolipoprotein AIV is also said to be produced through the peroxisome proliferated
receptor activators (PPARs) signalling pathway. PPARs are transcription regulators
which play a major role in metabolic and inflammatory regulation with far reaching
medical implications (Feige et al., 2006).
Figure 6.8: PPAR signalling pathway (KEGG pathways)
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6.2.3 Bioinformatics review of C-reactive protein
C-reactive protein (CRP) encoded by the Crp gene is 230 amino acids long and a
completely sequenced protein found in the plasma. It is homopentamer (pentaxin or
pentraxin) having a discoid arrangement of 5 non-covalently bound subunits that are
further processed into its mature form. Two of the five chains form a dimer linked by
two interchain disulfide bonds located in the C-terminal heptapeptide and specific to
rat CRP. Several functions have been associated with CRP. Most of the functions are
associated with the host defence by promoting the agglutination, bacterial capsular
swelling, phagocytosis and complement fixation through its calcium dependent
binding to phosphorylcholine. It can interact with DNA and histones and may
scavenge nuclear material released from damaged circulating cells. CRP is acting
with an aid of the 2 calcium ions per subunit as cofactors.
Figure 6 9: C-reactive protein structure as retrieved from the database
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C-reactive protein is associated with inflammation in most studies. In the KEGG
pathways (www.kegg.jp/kegg/pathway.html) CRP has been found to be orthologous
to various proteins that play a role in nitrogen metabolism. The CRP levels were high
in the high caloric diet fed groups and this elevation cannot be associated with
inflammation in this study. However CRP is a sensitive marker for a systemic
inflammation (Visser M, 1999). The high implication or association of CRP with
inflammation has been argued and other possibilities have been pointed out of which
ageing has also been one of the factors associated with rise in CRP levels (Kushner,
2001). There are a lot of studies that were done in inflammation that proved that the
elevation of CRP is inflammation related. Furthermore, the accumulation of CRP has
been associated with CHD because of various factors including the binding of CRP to
LDL and its deposition to the most atherosclerotic plaques (Pepys and Hirschfield,
2003). Studies on CRP would be instrumental in obesity focused studies and CRP as
a biomarker might be a challenge at the moment but it has been responsive for the
groups that were fed high caloric diet in this study. Studies towards biomarker
discovery can prove CRP to be of importance in obesity but that is not in the scope of
the current study but CRP is a potential biomarker.
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Figure 6.10: Nitrogen metabolism: Reduction and fixation (KEGG pathways)
6.2.4 Bioinformatics review of fetuin A
Fetuin A can be called alpha 2 HS glycoprotein or glycoprotein PP63. It is
encoded by the Ahsg or Fetua gene that is synthesized in the liver and secreted by
hepatocytes in the blood. The protein is 352 amino acids long with molecular
weight of 63 kDa containing bone siliac acid. It is known to inhibit both insulin
receptor tyrosine kinase activity and insulin stimulated receptor
autophosphorylation and concomitantly antagonize the mitogenic effect of the
hormone in cultured rat hepatoma cells.
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Figure 6.11: Fetuin A structure taken from Uniprot database (http://www.uniprot.org)
Fetuin A is also increased in expression with high caloric diet compared to the control
group which can prove to be a bad thing to the metabolism as mentioned above that it
inhibits insulin related function.
6.2.5 Bioinformatics review of fetuin B
Fetuin B also referred to as a Fetuin-like protein IRL 685 is a 378 amino acids protein.
It is encoded by the Fetub gene. Fetuin B belongs to the Fetuin family which itself
belongs to the cystatin superfamily and it is also proven that Fetuin A and Fetuin B are
homologous (Olivier et al., 2000b). In the study by Denecke et. al. (2003) fetuin B
was shown to be expressed more in the liver. Functional analysis performed in
the former study identified similarity between fetuin A and fetuin B in that both
inhibit phosphate calcium precipitation with more activity shown by fetuin A. The
information on fetuin B is not much compared to the information on fetuin A but the
research on the functions of fetuin B in the body is still under investigation. The
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structures for fetuins are similar as it can be seen in the previous and current section.
Searching information on database revealed more information on fetuin A than on
fetuin B with literature mentioning the identification of fetuin A to precede that of
fetuin B.
A B
Figure 6.12: Fetuin B (A) and Kininogen 1 (KNG) (B)
The pathway search on KEGG pathways identified orthology for fetuin B and
kininogen 1(KNG). Fetuin B had been associated with kallikrein-kinin system in the
complement a n d c o a g u l a t i o n c a s c a d e s . Kinins a r e e x p l a i n e d a s t h e
m o l e c u l e s involved in vascular tone regulation and inflammation (Costa-Neto
et al., 2008). Many studies have referred to obesity as an inflammatory associated
disease. There was an increase in fetuin B with development of obesity in our study
that might be the response that was counteracting the development of obesity.
Recent study revealed the reduction of fetuin B in the obesity prone rats compared to
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the obesity resistant rats (Choi et al., 2012). The scope of the current study is not an
in-depth study of pathways but the revelation of the possible functions of the proteins
that were identified to be deregulated with obesity development. The results on
fetuin B could be a step towards a potential candidate for biomarker or intervention
target. The implication of fetuin B in the inflammatory related pathway could be an
answer to the merging information when obesity and inflammation is studied.
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Figure 6.13: Complement and coagulation cascade (KEGG pathways)
6.2.6 Bioinformatics review of hemopexin
Hemopexin is a 460 amino acids protein encoded by Hpx gene. It is expressed in
the liver and secreted into the plasma. It is completely sequenced and its
function is binding the heme and transports it to the liver for breakdown and iron
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recovery. The free hemopexin returns to the circulation.
Figure 6.14: Hemopexin structure taken from the Uniprot database
Western blot was used to determine the difference seen while analyzing the images
by PD Quest. Transferrin has been shown not to change in the blood despite the
disease states (Wilkins et al., 2005). Transferrin was used as a loading control for the
Western blots and showed no change in expression for all the time points. The
changes were seen at week eight for all the proteins. There might be an earliest time
than eight weeks where the difference in protein expression commences at blood
level. Sampling was performed at baseline, four days, four week and eight weeks and
all these time point did not show differences between the groups for three earlier time
points but showed difference at week eight. There was an increased expression of C-
reactive proteins for the rats on high fat diets after eight weeks.
The other validated protein was the apolipoprotein AIV as shown by the PD Quest
analysis to be more than two-fold enhanced. Validation at termination showed the
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groups fed on high fat diets to be enhanced compared to the control group. The
difference in the apolipoprotein AIV was confirmed by using the albumin containing
sample because the difference was picked on the same sample by PD Quest. The
difference with the use of the Western blot confirmed the enhanced expression of the
apolipoprotein AIV in high fat diet fed groups (Figure 5.7.2).
The fetuin A and fetuin B expression was also confirmed. The expression of Fetuin A
and Fetuin B also got enhanced like the C-reactive protein and apolipoprotein AIV.
The reduced expression showed by the alpha 1 macroglobulin-like in high caloric diet
fed groups was not confirmed due to the unavailability of the antibodies against the
protein. There was no supply for either Western blot or ELISA. The expression for
the fetuin A is shown in Figure 5.7.3 and Fetuin B in Figure 5.7.4. There was no
confirmation by western blot for hemopexin-like which was found to be up-regulated
with development of obesity.
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6.8 Discussion
The use of proteomics to reveal the changes in protein serum expression successfully
revealed three proteins that were up-regulated and one down regulated protein in the
albumin depleted sample while one up regulated protein was found in the serum
containing sample. The proteins that were identified using the mass spectrometry
analysis were alpha 1 macroglobulin-like and hemopexin-like in the albumin depleted
sample. In the albumin containing sample apolipoprotein AIV was identified using the
mass spectrometry. Other proteins were identified with an aid of the 2D map as taken
from the inflammation study by (Gianazza et al., 2002a). The overall number of
proteins as identified using the map and mass spectrometry summed up to six
proteins that were above two-fold up-regulated or down regulated with development
of obesity.
Western blot validation of results also showed the up regulation of proteins at
termination time point which took place at week eight of  the experiment. Four
proteins were validated using the Western blot and the antibodies against alpha 1
macroglobulin were not available. The study had only four blood collections for
serum. The difference in protein expression was only seen at the termination time
point (week eight) and Western blot verified this for proteins that were verified. The
gap between week four and week eight seems to be big enough for a possibility that
the differential expression could have been earlier than week eight. There should have
been more information to clearly identify when the changes in the serum protein start
to take place should have been collection in week five, six and seven. The results
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confirm the PD Quest analysis that identified the differences in protein expression for
the animals on high fat diet compared to the control group. The identifications by
mass spectrometry also made firm the accuracy of the MALDI TOF in identifying the
proteins that were identified as deregulated proteins. There is a confidence in the map
as chosen to be used for other identifications because there was a similarity in the
identifications with what was seen on the 2D map. The outcomes of the proteomics
approach gives an indication of proteomics as a tool to study the changes at a protein
level due to obesity revealing proteome change in serum. With the readily available
information in the form of bioinformatics will be efficient in acquiring information of
proteins found. Bioinformatics has been used successfully to acquire the information
on identified proteins. The readily available information from Expasy is useful
because the known information has been used to find the k-values used in the quest
for ortholog information as obtained from the KEGG pathway database.
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Chapter 7: General Discussion
7.1 Discovery of candidate biomarkers of obesity using Proteomics
Diet has been highly implicated in development of obesity and the obesity associated
health risks with diabetes being the well pronounced because of the insulin resistance
that kick start after obesity development and vice versa. The use of high caloric diet is
in the forefront of obesity research as a way of finding out the effect that diet has in
obesity development studies. The balance in lipid breakdown (lipolysis) and lipid
synthesis (lipogenesis) is of crucial importance with mitochondria getting to be of
high interest because of its crucial role in fatty acid oxidation. There is less literature
on mitochondrial function in rodent models of high fat diet (HFD) induced obesity
and they are inconclusive possibly  due to different experimental conditions like
the type and content of dietary fat, composition of other macronutrients, duration of
the consumption and the amount of calories consumed (isocaloric vs hypercaloric)
(Shiraev et al., 2009). Obesity-related imbalance in the fatty acid supply and
utilization results in excessive accumulation of intrahepatic TAG and the
development of liver disorders such as non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (Ciapaite et al., 2011).
In this study we looked at the effect of different high caloric diets in inducing obesity
and the effect of such diets in the protein expression in the serum. Supplementation of
the protein with the powdered milk instead of the casein which is not natural or
condensed milk which increases the sweetness of the diet compared to the control diet
is the new approach to our knowledge especially the use of BF diet. Obesity from
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overconsumption of HFD is characterised by an abnormal increase in adipose tissue
mass, mainly resulting from the excessive storage of TG within adipocytes (Ha et al.,
2011). This has been seen in our study as well with high adiposity index for the L diet
fed group compared to the LF fed group which are diets of similar fat type with half
the amount of fat for the LF and supplementation of the calories with protein from
milk. The same was also the case with the adiposity index of the BF fed group that
was lower than that of L fed group.
There is a rise in interest of knowing the fatty acid content of the diets that are used in
nutritional studies in order to have a complete picture of the fats used than the amount
of fat used based on weight. It is not only the fatty acids but also carbohydrates and
proteins are being studied for their role in satiety which is one of the contributors to
the control of body weight accumulation. An increased protein intake diet-related
ketosis, and low glycemic index food consumption have been suggested to decrease
appetite (Parra et al., 2008). Mediterranean diets which include nuts and olive oil
have salutary health effects. These foods have low content of saturated fatty acids
(SFA) but a high content of unsaturated fatty acids, mainly polyunsaturated fatty
acids (PUFA) in walnuts and monounsaturated fatty acids (MUFA) in olive oil
(Casas-Agustench et al., 2009).
Saturated fatty acids are associated with high intake compared to the unsaturated fatty
acids which is due to the differences in satiety (Kien et al., 2005). Other studies
similar to this f o u n d no differences between  saturated and unsaturated fat
containing meals in terms of satiety (Poppitt et al., 2005, Cooper et al., 2011). Our
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study also showed no difference in the intakes that could be associated with satiety
because the food intakes were not differing significantly. Studies using labelled FAs
have shown that oleic acid and other unsaturated FAs are more readily oxidized than
are saturated FAs (Kien et al., 2005). This might contribute to the difference that was
seen in fat pad weights for the rats that were fed L diet when compared to other high
caloric diets where significant difference was seen. Another parameter that should be
noted is that the other high caloric diets also had fat content that was less than the L
diet and protein that is high but as stated in the literature the energy utilised for
conversion of protein to fat for storage is higher than the energy that is used for
storage of fats. The variation in the diets used in this study covers the scenarios in
different diets because diets have been studied individually as high fat diet or high
protein diet with comparison to the maintenance. This study answers the variation of
different energy sources in one experiment.
The use of weight and height for diagnosis of obesity is useful to date but with some
shortfalls because the weight doesn’t tell the weight from fat. Weight gain for the rats
that were fed high caloric diets was significantly different from the control group as
early as the second week for the animals fed L diet. All the animals were significantly
different on the third week compared to the control. Considering a significant
difference in the adiposity index but no significant difference in the body weight for
the animals fed high caloric diets is indicative of the shortfall that can be brought
about by the use of body weight for muscular subjects that are not high fat depots. It
is not disputable that the use of parameters like BMI and WHR are useful and gives
results in a short space of time especially for epidemiological studies. The
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supplementation of this information by the newly identified approaches would be
useful in improving the accuracy in the diagnosis of obesity. Proteomics as an
emerging line of research and is promising to give the answers to the phenotype
related changes in the body and the changes revealed by the proteomics downstream.
It is well known that the genetic makeup and the environmental exposure leads to
obesity development. The improvement in the protein research with the discovery of
2D PAGE has enabled the studying of proteins with enhanced output. The invention
of the soft ionization in the late 1980s of soft ionization  techniques leading to
MALDI-TOF MS has  made possible the identification of proteins (Wang et al.,
2006). Cancer research utilised proteomics approach for years before the diabetes and
obesity research took the proteomics route. The proteomics has been applied to study
tissues including liver (Wang et al., 2011), WAT (Joo et al., 2011) and skeletal
muscle (Kim et al., 2010) to identify the protein response with obesity development.
The outcomes on tissue samples were showing the expression of proteins to be
different between rats fed high fat diet and the rats on maintenance diet.
A strong need to study the proteomics in the blood has been recommended for
various reasons. Amongst the noted reasons are the less invasiveness of the use of
blood and because the secreted protein migrate between tissues through blood (Choi
et al., 2010). The study of plasma proteome recently published showed seven protein
that are differentially expressed when comparing rats fed HFD with rats on
maintenance diet (Liu et al., 2012). Unlike in our study the rats that were used in this
study were further studied based on their ease of developing obesity (obesity prone)
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and resistance to obesity (obesity resistance). Seventeen proteins were found to be
differentially expressed between the groups of which seven of those proteins were
significantly changed upon HFD feeding. In our study increasing calories altered six
proteins, with five up-regulated proteins and one down-regulated protein in response
to diet. Another difference between the two studies is the use of serum in our study
and the depletion method that resulted into two portions with the down-regulated
protein identified in the albumin containing portion. All the five up-regulated proteins
were found in the albumin depleted portion.
MALDI MS identification of the differentially expressed proteins identified up-
regulation of apolipoprotein AIV, C-reactive protein, Fetuin A, Fetuin B and
hemopexin in the albumin depleted sample. The protein spot in the albumin
containing sample (down-regulated protein) was also subjected to MALDI MS and it
was identified to be alpha   1 macroglobulin. Down-regulation of alpha   1
macroglobulin was reported before in the study on serum where the protein was seen
to fade with development of obesity (Zhao et al., 2008). Similar results were reported
in the plasma with down-regulation of alpha 1 macroglobulin with HFD diet feeding
in both OP and OR rats (Choi et al., 2010). Recently it was shown in the study of
serum proteome in both male and female rats that alpha 1 macroglobulin is down-
regulated by HFD feeding irrespective of gender. The studies together with the
current study suggest alpha 1 macroglobulin to be a potential marker of increased
caloric intake with less dependence of caloric source, gender and susceptibility of
individual to obesity development.
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These findings are corresponding with the studies done before. The study performed
by Matsumura, et. al. (2006) using OLEFT rats, which presents metabolic disorder
and type 2 diabetes comparing to the LETO which are resistant to metabolic disorders
as a control revealed the difference at the serum proteome level. These results were
obtained by the use of two-dimensional liquid chromatography system. There was an
increase in apoliporotein AIV which is corresponding with the findings that were
found in our study using PD Quest image analysis. The apolipoprotein AIV is the
only lipoprotein that is directly influenced by the dietary lipids (Whited et al., 2005).
The study by Jung-Won Choi et. al. (2012) reported no significant difference in
apolipoprotein AIV between the rats on LFD and OP rats whereas significantly
reduced levels of apoAIV were seen on the OR rats. In a separate study by Liu
et. al. (2012), unexpected results were seen whereby low levels of apoAIV were seen
with high fat diet in both males and females. Study in prepurbetal children shows that
the response to obesity development is marked by the rise in apolipoprotein AIV
which is strengthening the possibility of apoAIV as obesity biomarker (Galata et
al., 2011). The varying reports on the apolipoprotein AIV response however makes
it not to be readily accepted as a reliable protein to look at for the changes triggered
by diet.
There are studies that reported the association of obesity with inflammation rendering
CRP to be responsive to inflammatory. The proteomics outcome of CRP showed the
increase in response to HFD in the current study. A different response of CRP to
HFD was seen in the plasma proteomics analysis of HFD fed rats whereby obese rats
show reduced CRP levels than lean rats (Choi et al., 2010). A study by Hao Liu, 2012
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reports the reduction of CRP with HFD feeding which was consistent for both male
and female rats. In the current study CRP expression was high with the feeding of
high caloric diet. A recent study showed that restricting calories in a high fat diet
reduces the expression levels of the CRP in the adipose tissue (Park et al., 2012). The
results that are available regarding the expression of CRP in the blood are differing
between studies in relation to various conditions. The study on human subject on
caloric restriction for weight loss was conducted in obese women to find the link
between CRP, obesity, insulin resistance and obesity (McLaughlin et al., 2002). The
results show that obese and insulin resistant individuals are having high CRP levels
that fall parallel with weight loss-associated insulin resistance improvements. Using
CRP as a biomarker is not possible because gender differences gives results that
differ in  relation  to  the race (strain),  nutritional  state and  various environmental
factors (Liu et al., 2012).
The expression of the proteins in the fetuin family such as fetuin A and fetuin B
also increased with HFD feeding. Similar results were found for the study in the
plasma whereby fetuin A was increased in response to obesity regardless of the
proneness to obesity in rats (Choi et al., 2010), but gender dependent because in
males there is a reduction in fetuin A with increase in females suggesting that fetuin
A increase protects females from obesity (Liu et al., 2012). Fetuin A has been studied
by various researchers to find the role that the protein plays in the body. Fetuin A has
been identified as a major protein during fetal life and is also involved in important
function such as inhibition of the insulin receptor tyrosine kinase activity, protease
inhibition activities and development-associated regulation of calcium metabolism
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and osteogenesis (Olivier et al., 2000a). The study on fetuin null mice showed that
the knocking down of fetuin serves as a protection against the development of insulin
resistance (Mathews et al., 2002).
Hemopexin which is the protein produced in the liver has been shown to increase in
the liver with obesity development in male and female obese rats (Wang et al., 2011).
In our study the expression of hemopexin was increased in the serum. This could be
potential advantage for future studies should hemopexin be studied in relation to the
metabolic processes in the liver. Having complete information will enable the use of
less invasive method which is obtaining blood compared to the use of biopsies to
obtain information about the obesity. Hemopexin studied in liver transplant studies
showed that it is fucosylated in relation to the transplant rejection in genetically
different models making it to be a potential indicator in studying the response (Pan et
al., 2010). The outcome of this study though it was focusing on different disease but
liver is known for its role in metabolism and toxicity of which hemopexin shows to
be a potential candidate in reporting the liver condition.
The use of proteomics is an approach that will speed the understanding of the body
machinery which is proteins. The understanding of proteins and their role in diseases
will enable the understanding of the proteins and the ways in which the proteins
operate in relation to what is taking place in the body. This will be advantageous
because the proteins and their state determine what is to happen in the body.
Understanding the diet induced obesity will be a positive finding because there is a
rise  in the diet related diseases that prevails due  to excess energy storage. The
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availability of the information centralization through bioinformatics will be a big
contributor to the continuation in the proteomics finding. Bioinformatics is covered in
the next section. The validation of the expressions by Western blot is a reliable
method and it is available to most laboratories over ELISA which is also a sensitive
and quantitative but with quite high cost than Western blot.
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7.2 Validation of candidate biomarkers of obesity using Western blot and
bioinformatics
The main advantage of looking at the protein expression is the understanding of the
functioning post translation. Various studies looked at the expression of protein in
relation to the diet used but most of the time they use one high fat diet and the control
diet which is limiting the results to one to one comparison of diets. In this study the
protein expression was performed in more than one high caloric diet. At the present
moment the outcome of protein expression obtained proteomics require the validation
of the results using the Western blot or other quantitative methods. The use of the
validation methods address the technical errors that can be encountered while
identifying the proteins as differentially expressed. Various studies use Western blot
as a method of choice for validation of proteomics results (Wang et al., 2011). Some
studies use ELISA and both the methods are preferred for their sensitivity.
The Western blot results for the proteins that were validated were corresponding with
the expressions as analyzed using PD Quest. The corresponding results promise the
potential of the use of proteomics in the future as a clinical procedure in screening for
diseases and possibly intervention can be done following proteomics outcomes. The
proteomics evolve at a high pace in recent times.
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7.3 Concluding remarks, conclusion and future perspectives
The study was able to reveal that the rise in adiposity can be reflected in the serum
proteome. This was shown by the biomarkers that followed the trend based on the
storage of fat by animals in different groups. This can be used in future to tell the
lifestyle of a person based on the profile looking at the abundance of the proteins that
are insulin resistance perpetuators. Fetuin A is known t o  p l a y  a role in insulin
resistance. Insulin resistance is one of the factors that contribute to a high prevalence
of obese diabetic subjects. The other proteins that gets enhanced during high caloric
intake which include CRP, apolipoprotein AIV, fetuin B and hemopexin rise interest
in studying them further which can lead to identification of their potential as
biomarkers in obesity. Alpha 1 macroglobulin reduction during obesity development
is also showing this protein to be a potential biomarker for obesity in the future. This
study managed to reveal the responsive proteins during obesity development of which
some quantitative methods could have been employed to come with levels of
proteins quantitatively to come up with quantitative amounts of proteins that can be
associated with obesity state or possibility of obesity development. Studying the
identified proteins was beyond the scope of this study. The study itself managed to
show that the trend in protein response is having relation to calories which will be a
powerful tool in the future in identification methods that are going to be used in
personal medicine since the caloric intake in this study showed to be having a
pattern for high caloric diets when compared to the control diet. Further studies for
identification of proteins that are associated with obesity and possibly alterations
with such proteins will be necessary to enable the combating of obesity.
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